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Statement regarding the United Kingdom 
The reference period for this risk assessment report includes 2019 and 2020 (up to the time of 
writing). The United Kingdom left the EU as of 1 February 2020. However, during the transitional 
period, the United Kingdom continues to participate in the EU Early Warning System on new 
psychoactive substances. Unless stated otherwise, for the purpose of this report, the term ‘Member 
States’ shall include the United Kingdom. 
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This publication presents the data and findings of the risk assessment on isotonitazene (N,N-diethyl-
2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine), carried out by the 
extended Scientific Committee of the EMCDDA on 26 May 2020.  
The Risk Assessment Report, which was submitted to the European Commission on 29 May 2020, 
examines the health and social risks of the drug, information on international trafficking and the 
involvement of organised crime, as well as a consideration of the potential implications of subjecting 
the drug to control measures. Isotonitazene is the first new psychoactive substance to be risk 
assessed under the Article 5c of Regulation (EC) No 1920/2006 (as amended by Regulation (EU) 
2017/2101). 
On the basis of the Risk Assessment Report the Commission adopted delegated act in order to add 
isotonitazene in to the definition of a drug in the Annex of the Council Framework Decision 
2004/757/JHA (as amended by Directive (EU) 2017/2103). This decision was adopted in the final 
stage of the three-step process — early warning, risk assessment and control of new psychoactive 
substances — established by Regulation (EC) 1920/2006 (as amended) and  Council Framework 
Decision 2004/757/JHA (as amended).   
Regulation (EC) 1920/2006 (as amended) and  Council Framework Decision 2004/757/JHA (as 
amended) allow the EU institutions and Member States to act on all new and potentially threatening 
narcotic and psychotropic drugs which appear on the European drug scene, with the EMCDDA and 
Europol, in collaboration with their respective networks playing a central role in the early detection of 
such substances as well as the harms caused by their use — information that underpins risk 
assessment, and, ultimately, decision-making. 
In this respect we would like to acknowledge the essential role played by the respective networks in 
the Member States — the Reitox national focal points — in collecting and providing national data. We 
would also like to acknowledge the role of Europol and Europol National Units, the European 
Medicines Agency (EMA) and the national competent authorities responsible for medicinal products, 
the European Chemicals Agency (ECHA), the European Centre for Disease Prevention and Control 
(ECDC) and the European Food Safety Authority (EFSA) that provided valuable input to the report, 
thus guaranteeing its truly multidisciplinary nature. 
Finally, we would like to thank all the participants in the risk assessment process for the high quality of 
work carried out. This procedure occurred under challenging circumstances, amidst the coronavirus 
(COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
The resulting report is a valuable contribution at European level, and provides clear support to political 
decision-making.  
Dr Anne Line Bretteville-Jensen 
Chair, Scientific Committee of the EMCDDA 
Alexis Goosdeel 
Director, EMCDDA  
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EMCDDA Initial Report on N,N-diethyl-2-[[4-(1-
methylethoxy)phenyl]methyl]-5-nitro-1H-
benzimidazole-1-ethanamine (isotonitazene) 
 
On 20 February 2020, the EMCDDA assessed the existing information on N,N-diethyl-2-[[4-(1-
methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (commonly known as 
isotonitazene), based on the following criteria: (1) reports of health problems; (2) reports of social 
problems; (3) reports of seized material; (4) pharmacological and toxicological properties and analogy 
with better-studied substances; and, (5) potential for further spread. 
The EMCDDA concluded that the assessment gave rise to concerns that isotonitazene may pose 
health or social risks at Union level, and, consequently, determined that an initial report should be 
produced. 
On 3 April 2020, the EMCDDA submitted to the Commission and Member States an initial report on 
the new psychoactive substance isotonitazene,in accordance with Article 5b of the Regulation (EC) 
1920/2006 (as amended). The report concluded that the health and social risks, caused by the use of, 
the manufacture of, and traffic in isotonitazene, as well as the involvement of organised crime and 
possible consequences of control measures, could be thoroughly assessed through a risk 
assessment procedure as foreseen by Article 5c of the Regulation (EC) 1920/2006 (as amended). 
The full text of the Initial Report can be found at: 
https://www.emcdda.europa.eu/publications/initial-reports/isotonitazene_en 
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Risk Assessment Report on a new psychoactive 
substance: N,N-diethyl-2-[[4-(1-
methylethoxy)phenyl]methyl]-5-nitro-1H-
benzimidazole-1-ethanamine (isotonitazene) 
Introduction 
New psychoactive substances can cause serious cross-border threats to health. In Europe, 
Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 
on the European Monitoring Centre for Drugs and Drug Addiction (recast) (as amended) (hereafter 
the ‘Regulation’) and Council Framework Decision 2004/757/JHA of 25 October 2004 laying down 
minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug 
trafficking sets up a three-step legal framework of early warning, risk assessment and control 
measures that allows the EU to rapidly detect, assess and respond to the public health and social 
risks caused by new psychoactive substances. The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is responsible for the first two steps in this system, namely operating the EU 
Early Warning System on new psychoactive substances (EU EWS) in close cooperation with Europol, 
and conducting risk assessments. The European Commission is responsible for proposing control 
measures. Thus, the legal framework allows the institutions of the EU and the Member States to act 
on all new psychoactive substances (NPS) that appear on the European drug market. 
In accordance with Article 5a of the Regulation, N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-
nitro-1H-benzimidazole-1-ethanamine (commonly known as isotonitazene) was formally notified as an 
NPS by the EMCDDA on behalf of Belgium on 26 August 2019. The notification was based on the 
identification of the substance in a collected sample of powder that was a test purchase from a private 
online vendor and which was received on 1 July 2019 (1). 
Based on the information reported to the EU EWS, and, in accordance with Article 5a of the 
Regulation, on 20 February 2020, the EMCDDA assessed the existing information on isotonitazene. 
The EMCDDA concluded that the assessment gave rise to concerns that isotonitazene may pose 
health or social risks at EU level, and, consequently, determined that an initial report should be 
produced in accordance with Article 5b of the Regulation. The initial report was submitted to the 
Commission and Member States on 3 April 2020. Based on the findings of the initial report, on 
17 April 2020, the Commission requested that the EMCDDA carry out a risk assessment on 
isotonitazene in accordance with Article 5c of the Regulation. 
This risk assessment report presents the summary findings and the conclusion of the risk assessment 
carried out by the Scientific Committee of the EMCDDA on isotonitazene. The report is intended for 
policymakers and decision-makers in the institutions of the EU. 
The report has been prepared and drafted in accordance with the requirements of Article 5c of the 
Regulation as well as the conceptual framework and the procedure set out in the EMCDDA risk 
 
(1 )  However, based on information subsequently reported to the EMCDDA concerning a seizure made by police in Estonia, 
isotonitazene has been available on the European drug market since at least April 2019. 
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assessment operating guidelines. It is written as a stand-alone document, which presents a summary 
of the information considered during the detailed assessment of the scientific and law enforcement 
information available at this time. The conclusion section of the report summarises the main issues 
addressed and reflects the opinions held by the members of the Scientific Committee. A list of the 
information resources considered by the Scientific Committee, including a detailed technical report on 
isotonitazene prepared by the EMCDDA (Annex 1), is provided below. 
In accordance with Article 5c of the Regulation, the meeting to assess the risks of isotonitazene was 
convened under the auspices of the Scientific Committee of the EMCDDA with the participation of five 
additional experts designated by the Director of the EMCDDA, acting on the advice of the 
Chairperson of the Scientific Committee, chosen from a list of experts approved by the Management 
Board of the EMCDDA. The additional experts were from scientific fields that were either not 
represented or not sufficiently represented in the Scientific Committee, and whose contribution is 
necessary for the balanced assessment of the risks posed by isotonitazene. A further six experts 
were observers to the risk assessment: two experts from the Commission, two experts from the 
EMCDDA, one expert from Europol, and one expert from the European Medicines Agency (EMA). 
The meeting took place on 26 May 2020. Owing to the ongoing response to the coronavirus (COVID-
19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the 
meeting was conducted by videoconference and hosted by the EMCDDA. 
The risk assessment was carried out on the basis of information provided to the Scientific Committee 
by the Member States, the EMCDDA, Europol, the EMA, the European Centre for Disease Prevention 
and Control (ECDC), the European Chemicals Agency (ECHA) and the European Food Safety 
Authority (EFSA). A list of the Scientific Committee members, observers and other participants 
attending the risk assessment meeting is annexed to this report (Annex 2). 
For the risk assessment, the Scientific Committee considered the following information resources: 
§ the EMCDDA technical report on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-
benzimidazole-1-ethanamine (isotonitazene) (Annex 1); 
§ the EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-[[4-(1-
methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene); 
§ open source information, including scientific articles, official reports, grey literature, internet 
drug discussion forums and related websites (hereafter ‘websites for people who use drugs’); 
§ additional information provided during the course of the risk assessment meeting by the 
participants; 
§ EMCDDA operating guidelines for the risk assessment of new psychoactive substances; 
§ Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 
12 December 2006 on the European Monitoring Centre for Drugs and Drug Addiction (recast) 
(as amended); and 
§ Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum 
provisions on the constituent elements of criminal acts and penalties in the field of illicit drug 
trafficking (as amended). 
Background 
During the mid-1950s, attempts to develop better and safer opioid analgesics led to the discovery of a 
series of 2-benzylbenzimidazole compounds with levels of analgesic potency several orders of 
magnitude higher than that of morphine. This group of structurally distinct opioid analgesics includes 
isotonitazene, the subject of this risk assessment report, as well as etonitazene and metonitazene, 
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which are closely related homologues, and clonitazene. Both etonitazene and clonitazene are 
controlled under the United Nations Single Convention on Narcotic Drugs of 1961 because of the 
potential risks they pose to public health, and, more specifically, because of their ability to produce 
morphine-like adverse effects, to suppress abstinence phenomena of a known morphine addiction 
and to sustain morphine addiction in experimental models. None of these 2-benzylbenzimidazoles 
has become an authorised medicine. 
Although the high analgesic potency renders the manufacture of this series of compounds attractive 
to clandestine chemists, until the first identification of isotonitazene in 2019, when it was first identified 
on the illicit drug market, only etonitazene had been sporadically encountered on the drug market. As 
of 26 May 2020, isotonitazene is the only substance from the 2-benzylbenzimidazole series of opioid 
analgesics notified to the EMCDDA as an NPS. 
Similar to other types of opioid analgesics such as morphine and fentanyl, the 2-benzylbenzimidazole 
compounds, including isotonitazene, produce most of their effects by activating the μ-opioid receptors 
(MOPs) in the central nervous system (CNS). The acute effects of this include euphoria, relaxation, 
analgesia (a reduced ability to feel pain), sedation (inducing a state of calm or sleep), bradycardia 
(slowing of the heart), hypothermia (dangerously low body temperature) and respiratory depression 
(slowing down of breathing). It is this last effect that poses the greatest danger to users, as, owing to 
the apparently high potency of some of these compounds, sub-milligram doses may cause life-
threatening poisoning from respiratory depression. Left untreated, this can lead to respiratory arrest 
(cessation of breathing) and death. Although the available information is limited, the 2-
benzylbenzimidazole opioids, including etonitazene and isotonitazene, are likely to have an abuse 
liability and dependence potential, similar to other opioid analgesics. 
Isotonitazene has been available on the drug market in Europe since at least April 2019. It is 
important to highlight that, as isotonitazene has emerged on the drug market only recently, no formal 
epidemiological studies have been conducted, which limits understanding of the frequency and 
patterns of use of the substance. Related to this, the presence of isotonitazene on the drug market 
and its involvement in serious adverse events (such as acute poisonings presenting to hospital 
emergency rooms and medico-legal death investigations) may be undetected because the substance 
is not routinely screened for in some forensic and toxicology laboratories in Europe. Therefore, the 
presence of isotonitazene on the drug market may be undetected in some areas. Analytical sensitivity 
related to the analysis of biological samples from serious adverse events may also be a potential 
issue, as the concentration of isotonitazene or its metabolites can be at sub-nanogram level (similar to 
the highly potent opioid carfentanil), which highlights a need for increased analytical scrutiny when 
testing for the substance. In addition, in some areas not all laboratories are part of national early 
warning systems; for this reason, the identification of isotonitazene may go unreported to the Reitox 
national focal points, and, as a result, to the EMCDDA. Finally, it is also important to note that, in 
some settings, the ongoing COVID-19 pandemic may have reduced the capacity of early warning 
systems, including forensic science and toxicology laboratories, to detect and report events involving 
isotonitazene, or, for that matter, any other NPS. 
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Chemical and physical properties and the methods and precursors 
used for manufacture 
Chemical and physical properties 
Isotonitazene belongs to the 2-benzylbenzimidazole group of opioid analgesics. In particular, it is a 5-
nitro-2-benzylbenzimidazole derivative. This group also includes the closely related homologues, 
etonitazene and metonitazene, as well as clonitazene. 
Isotonitazene differs from etonitazene and metonitazene in the substitution at the para-position of the 
benzyl moiety, which is an isopropoxy group in isotonitazene, an ethoxy group in etonitazene and a 
methoxy group in metonitazene. Isotonitazene differs from clonitazene in the replacement of the 
chloro halogen atom with the ethereal isopropoxy group. The n-propoxy isomer, protonitazene, is also 
known. The chemical structures, molecular formulae and molecular weights of these compounds are 
provided in Figure 1. 
FIGURE 1  
Chemical structure, molecular formula and molecular weight of isotonitazene, 
etonitazene, metonitazene and clonitazene. 
Isotonitazene Etonitazene Metonitazene Clonitazene 
    
Molecular formula: 
C23H30N4O3 
 
Molecular weight: 
410.51 
Molecular formula: 
C22H28N4O3 
 
Molecular weight: 
396.48 
Molecular formula: 
C21H26N4O3 
 
Molecular weight: 
382.46 
Molecular formula: 
C20H23ClN4O2 
 
Molecular weight: 
386.88 
The free base and salts of isotonitazene are solids. Identifications of isotonitazene reported to the 
EMCDDA include both the free base and the hydrochloride salt. 
The measured melting point for isotonitazene hydrochloride salt is 172–173°C. 
Isotonitazene is lipophilic (calculated log P = 4.85). 
Isotonitazene, as both the free base and the hydrochloride salt, is soluble in methanol and in dimethyl 
sulfoxide (DMSO). Although no experimental data are available, the salts of isotonitazene, similar to 
those of etonitazene, are expected to be sufficiently water-soluble for the injectable administration of 
effective doses. 
No studies have examined the stability and reactivity of isotonitazene. As a base, the substance 
readily forms salts with inorganic or organic acids. Chemical reducing agents are expected to convert 
the nitro group into an amino group. 
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The analytical identification of isotonitazene in physical and biological samples is possible using 
several analytical techniques. These include chromatographic and mass-spectrometric techniques. 
Certified analytical reference material is available for isotonitazene and for other similar substances, 
such as protonitazene. The availability of analytical reference material is important for correct 
identification and for facilitating the quantification of isotonitazene in physical and biological samples. 
Isotonitazene is not expected to give a positive response to immunoassays developed for opioids. 
Methods and precursors used for manufacture 
There is no information on the actual manufacturing methods or chemical precursors used to 
synthesise the isotonitazene that has been identified on the drug market in Europe. Information from 
one seizure made by customs suggests that at least some isotonitazene on the market in Europe has 
been supplied from China. Although the synthetic routes reported in the scientific literature involve 
three or four steps, depending on precursor availability, they are straightforward and make use of 
common manufacturing equipment. The starting materials for either synthetic route are readily 
available. The multi-step production of isotonitazene requires basic knowledge of and experience in 
synthetic organic chemistry. 
Pharmaceutical forms 
Information on the pharmaceutical forms available for isotonitazene is limited. Isotonitazene can be 
administered orally as a powder, as tablets or as a solution; it can also be administered intranasally or 
sublingually via spray or snorted (insufflated), inhaled by vaporising e-liquid solutions (‘vaping’), 
inhaled by smoking or vaporising the ‘free base’, and injected. 
Given the illicit nature of the trade in isotonitazene, the composition of products containing 
isotonitazene is likely to vary over time and place, as well as based on the specific location in the drug 
supply chain from which the product was obtained (e.g. from the manufacturer, wholesaler, retailer or 
at street-level illicit opioid markets). In Europe, isotonitazene has been seized by law enforcement 
predominantly in powder form; in two cases it has also been seized as a liquid. Information on the 
amount of isotonitazene present in seized powders (chemical purity) has not been reported; however, 
information from police seizures in Estonia noted the presence of ‘common sugars’ in at least some of 
the samples (not specified further), while one seizure made by police in Latvia also contained 
fentanyl. Results from the analysis of a collected sample of isotonitazene in powder form that was 
purchased from an online vendor noted that isotonitazene was estimated to be of a high purity. 
Pharmacological and toxicological properties 
Pharmacological properties 
There is limited information on the pharmacological properties of isotonitazene. Although 
isotonitazene has not been formally studied in humans, a recent study has demonstrated that it is a 
highly potent, full MOP agonist in vitro, while an older study has demonstrated that it has potent 
morphine-like centrally mediated analgesic effects in an animal model of experimentally induced pain. 
As a result of its lipophilicity, isotonitazene is expected to be rapidly absorbed and to readily cross the 
blood–brain barrier. Taken together, this information suggests that isotonitazene will also act as an 
opioid analgesic in humans. The major pharmacological effects of such opioid analgesics, including 
their analgesic activity, are due to their activation of the MOP receptor. In addition to their analgesic 
properties, a notable feature associated with opioid analgesics is that they cause dose-dependent 
respiratory depression, which in overdose can be life-threatening. Other opioid effects include miosis, 
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sedation, bradycardia, hypothermia, constipation, physical dependence and changes in mood (e.g. 
euphoria). 
According to preclinical studies with the related substance etonitazene, naloxone antagonises the 
effects of the opioid. In an early human clinical trial, respiratory depression and coma induced by 
metonitazene were antagonised by a prompt injection of nalorphine. 
There is limited information on the pharmacokinetics, including half-life and potentially bioactive 
metabolites, of isotonitazene. 
No information is available on any potential activity of isotonitazene at other pharmacological targets. 
Toxicological properties 
The toxicological properties of isotonitazene have not been studied. Despite the lack of experimental 
data, observations that antinociceptive potency in general correlates with acute toxicity within the 2-
benzylbenzimidazole group of opioid analgesics — including for etonitazene or metonitazene, which 
are both closely related homologues of isotonitazene — suggest that the acute toxicity of 
isotonitazene, at least in animal models, may be much greater than morphine and similar to that 
estimated for etonitazene or metonitazene. 
Health risks 
There is limited information on the health risks posed by isotonitazene. Based on the available 
information, the health risks are likely to be similar to those for other opioid analgesics. In particular, 
the most serious acute health risk from isotonitazene is likely to be respiratory depression, which in 
overdose can lead to apnoea, respiratory arrest and death. This risk will be exacerbated by the use of 
other CNS depressants. 
Acute toxicity 
There is limited information on the acute toxicity of isotonitazene. Based on the available information, 
the health risks are likely to be similar to those for other opioid analgesics. These include sedation, 
bradycardia, hypothermia and respiratory depression. 
While there is no information on the clinical features of poisoning caused by isotonitazene, they are 
likely to include miosis, a reduced level of consciousness or unconsciousness, and respiratory 
depression. Similar to other opioid analgesics, the most serious acute risk arising from the use of 
isotonitazene is likely to be respiratory depression, which in overdose can lead to apnoea, respiratory 
arrest and death. Although there is no reported clinical experience with poisonings caused by 
isotonitazene, based on the pharmacological properties of isotonitazene, naloxone is expected to 
work as an antidote. Owing to the short half-life of naloxone, it is possible that larger than normal 
doses and repeated doses may be required to manage the poisoning in some cases; longer periods 
of observation may also be required. 
Similarly to other opioid analgesics, the use of isotonitazene with other CNS depressants, including 
other opioids, sedatives/hypnotics, alcohol, pregabalin, gabapentin, tranquillisers and sedating anti-
histamines, is likely to produce additive depressant effects, which can increase the risk of life-
threatening respiratory depression. 
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Acute poisonings 
No cases of acute poisoning involving isotonitazene have been reported to the EMCDDA or published 
in the scientific literature. 
Deaths 
A total of 23 deaths associated with isotonitazene have been reported by four countries to date: 
Germany (1 case), the United Kingdom (1 case), Canada (3 cases) and the United States (18 cases). 
The role of isotonitazene in these deaths is unknown. 
Deaths reported in Europe 
A total of two deaths involving isotonitazene have been reported to the EMCDDA, by Germany and 
the United Kingdom. No further information is currently available for the death reported by Germany. 
The United Kingdom reported a death with confirmed exposure to isotonitazene that occurred in 2019. 
Alongside isotonitazene, butyrylfentanyl, despropionyl fentanyl (4-ANPP) and despropionyl 
fluorofentanyl were also identified in post-mortem biological samples; all the substances were 
estimated to be present in below ng/ml concentrations. No further details on the case are currently 
available. 
Deaths reported elsewhere 
In addition to the cases in Europe, deaths in which isotonitazene was identified in post-mortem 
samples have been reported in Canada (3 cases) and the United States (18 cases). 
In Canada, isotonitazene was identified in three deaths during 2019. The deaths occurred in Alberta 
in March, September and October 2019. No further details are available. 
In the United States, isotonitazene was identified in 18 deaths that occurred between August 2019 
and January 2020; all cases were medico-legal death investigations. Two thirds of individuals were 
male (n = 12; 67 %). The mean age was 41 ± 12 years (median 41 years) and ranged from 24 to 66 
years. 
The mean concentration of isotonitazene in blood samples (n=18) was 2.2±2.1 ng/mL (median: 1.75 
ng/mL, range 0.4-9.5 ng/mL) (central or peripheral blood). The lowest concentration of isotonitazene 
in blood was encountered in two cases in which no other opioids were present. The mean 
concentration of isotonitazene in urine samples (n =6) was 2.4±1.4 ng/mL (median 2.7 ng/mL, range 
0.6-4.0 ng/mL). The concentration of isotonitazene in a single sample of vitreous fluid was 0.1 ng/mL. 
It is important to note that quantitative results for isotonitazene were at the sub-nanogram level, which 
highlights a need for increased analytical scrutiny when testing for the substance. 
Based on information from the death investigations (n = 8) and forensic toxicology results (n = 18), at 
least some of the individuals were high-risk drug users and included people who had a history of 
injecting established illicit opioids, such as heroin and fentanyl. Isotonitazene was identified along with 
one or more other psychoactive substances (controlled drugs and NPS) in all the deaths, which 
suggests that polydrug use was common in these individuals. Other findings in blood were as follows. 
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§ In addition to isotonitazene, one or more other types of opioids were identified in 10 (56 %) of 
the cases; these included fentanyl (n = 6), morphine (n = 3) (including 6-monoacetylmorphine 
in one case), tramadol (n = 4), piperidylthiambutene (n = 2) and U-47700 (n = 1). 
Isotonitazene was the only opioid identified in the remaining eight cases. 
§ Benzodiazepines were identified in 16 (89 %) of the cases; most of the identifications related 
to flualprazolam (n = 11) or etizolam (n = 8). 
§ Stimulants were identified in six (33 %) of the cases: cocaine was identified in 4 (22 %) cases 
and amphetamine and methamphetamine were identified in two (11 %) cases (in one of these 
cases MDMA and MDA were also identified). 
§ Naloxone (an antidote used in opioid overdose) was identified in six (33 %) of the cases. This 
includes two cases in which isotonitazene was the only opioid identified. 
Physical, mental and behavioural effects 
The physical effects of isotonitazene have not been studied. Based on the pharmacological properties 
of the substance, as well as information from the study of the closely related substances etonitazene 
and metonitazene, it is likely that the effects of isotonitazene are similar to those commonly reported 
for other opioid analgesics, including miosis, analgesia, respiratory depression, constipation, 
bradycardia and hypothermia. 
The mental and behavioural effects of isotonitazene have not been studied. Based on the 
pharmacological properties of the substance, as well as on information from the study of the closely 
related substances etonitazene and metonitazene, it is likely that the effects of isotonitazene are 
similar to those commonly reported for other opioid analgesics, including dizziness, drowsiness, 
mental confusion, incoordination, relaxation and euphoria; at higher doses, sedation and profound 
intoxication would be expected. 
There have been no studies of the effects of isotonitazene on the ability to drive and operate 
machines. However, it is well established that opioid analgesics impair the mental and physical ability 
required to drive and operate machines. This effect is likely to extend to isotonitazene. 
Chronic toxicity 
There is no information on the chronic toxicity of isotonitazene. 
Abuse liability and dependence-producing potential 
The abuse liability and dependence-producing potential of isotonitazene have not been studied. 
However, etonitazene and metonitazene, both of which are closely related to isotonitazene, as well as 
clonitazene, have been studied to varying degrees in animals and, to some extent, in humans. Similar 
to other MOP receptor agonists, such as morphine, and fentanyl, these studies suggest that members 
of the 2-benzylbenzimidazole group of opioids, including isotonitazene, are likely to have an abuse 
liability and dependence-producing potential in humans. Research will be required in order to 
determine the degree of such effects. 
Other relevant information 
Accidental exposure, including occupational exposure, to isotonitazene — especially inhalation or 
ingestion — may pose a risk of poisoning to those who may come into contact with the substance. 
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This includes the family and friends of people who use isotonitazene, law enforcement, emergency 
personnel, medical and forensic laboratory personnel, as well as individuals in custodial settings and 
postal services. In addition to exercising extreme caution when handling materials suspected to 
contain isotonitazene, working environments and personnel should be equipped with appropriate 
protective equipment. The antidote naloxone should be readily available to personnel in sufficient 
quantities; training in resuscitation and naloxone administration should also be available. 
Social risks 
There is no specific information on the social risks posed by isotonitazene. There is no information on 
whether or not criminal groups are involved in the manufacture, trafficking and distribution of 
isotonitazene within Europe. 
As isotonitazene acts as an opioid analgesic, it is possible that any such risks may have some 
similarities with those associated with the use of established illicit opioids, such as heroin or fentanyl 
and its derivatives. Such risks include negative impacts on social functioning and criminal activities, 
such as the involvement of organised crime in the manufacture, trafficking and distribution of the 
substance. 
Extent and patterns of use, availability and potential for diffusion 
There is limited information on the extent and patterns of use, availability and potential for diffusion of 
isotonitazene in Europe. As isotonitazene has been on the drug market for only a short period of time, 
no formal epidemiological studies have been conducted, which limits the understanding of the extent 
and patterns of use, as well as the potential for diffusion. In relation to this, the presence of 
isotonitazene on the drug market and its involvement in serious adverse events may be undetected in 
some areas because the substance is not routinely screened for in some forensic laboratories. 
Isotonitazene has been available on the drug market in Europe since at least April 2019, when it was 
seized for the first time by police in Estonia. The most recent identification of isotonitazene reported to 
the EMCDDA was a seizure made by police in Latvia in January 2020. As of 1 May 2020, it has been 
identified in six Member States: Belgium, Estonia, Germany, Latvia, Sweden and the United Kingdom. 
These detections relate to police seizures reported by Estonia, Germany and Latvia, a customs 
seizure reported by Sweden, a collected sample reported by Belgium, and biological samples from a 
death case reported by the United Kingdom. While the seized quantities are relatively small, they 
should be seen within the context of the high potency of isotonitazene. 
Based on information from a seizure reported by Sweden, it appears that at least some of the 
isotonitazene on the market in Europe has been supplied from China. Isotonitazene is sold online as 
a powder in wholesale and small amounts; it is also sold as ready-to-use nasal sprays. Based on 
limited information from police seizures reported by two Member States (Estonia and Latvia) it is 
presumed, but not confirmed, that isotonitazene has been sold on the illicit opioid market at street 
level and is being injected intravenously by people who use opioids. Overall, the demand for 
isotonitazene, and potential for diffusion, is unknown. 
Isotonitazene may be deliberately sought after by some people, particularly those who self-
experiment with a range of psychoactive substances (so-called ‘psychonauts’); others, such as those 
who purchase it on street-level opioid markets, may be unaware that they are using a substance that 
presents an inherent risk to the individual. Although the drug situation is different from that in Europe, 
information from deaths with confirmed exposure to isotonitazene in the United States found that at 
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least some of the individuals were high-risk drug users and included people who had a history of 
injecting opioids such as heroin. In addition, isotonitazene was identified along with one or more other 
psychoactive substances (controlled drugs and NPS) in all the deaths, which suggests that polydrug 
use was common in these individuals. In particular, the use of other CNS depressants such as other 
opioids and benzodiazepine sedative/hypnotics was very common in these individuals. 
Information on the dosage regimens used for isotonitazene is limited. The small number of anecdotal 
self-reported experiences on websites for people who use drugs suggest that, similar to other opioid 
analgesics, the dosage regimens used for isotonitazene can differ within and between individuals. It is 
not possible currently to discern typical dosage regimens. These also depend on the tolerance of the 
person who is using the substance, the use of other drugs and the desired effects. Furthermore, the 
purity, amount and/or composition of the substance ingested are not typically known by the people 
who are using the substance. In addition, the actual composition of the substance may differ over time 
and place. Nonetheless, a range of dosage regimens, including differing routes of administration (e.g. 
intravenous injection and nasal insufflation by spray), formulations (dosage forms) and the schedule 
of doses of isotonitazene — including the amount taken each time, time between doses and the 
duration of use — have been noted on websites for people who use drugs; polydrug use has also 
been noted as part of some of these self-reported experiences. 
Commercial and industrial uses, the extent of such use and its use for 
scientific research and developmental purposes 
Based on the available information reported to the EMCDDA from the EMA, it appears that 
isotonitazene is not an active substance in any medicinal product for human use or in any veterinary 
medicinal product in Europe. However, although unlikely, the use of isotonitazene as an active 
substance in medicinal products prepared extemporaneously or in investigational medicinal products 
cannot be excluded in some Member States. 
There is currently no information suggesting that isotonitazene is used for legitimate purposes, 
including commercial and industrial uses, other than a scientific research or forensic application. 
Other relevant information 
Restrictive measures 
International restrictive measures 
At international level, isotonitazene is not controlled under the United Nations Single Convention on 
Narcotic Drugs, 1961, nor under the Convention on Psychotropic Substances of 1971. Isotonitazene 
has not been subject to assessment nor is it currently under assessment by the United Nations 
system. 
National restrictive measures 
Twenty-two Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Finland, 
France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, the Netherlands, Portugal, 
Romania, Slovakia, Slovenia and Spain) reported that isotonitazene is not subject to restrictive 
RISK ASSESSMENT REPORT I Isotonitazene 
16 
measures at national level. Turkey also reported that isotonitazene is not subject to restrictive 
measures at national level. 
Isotonitazene is subject to restrictive measures in six Member States: in Estonia, Latvia, Poland and 
Sweden the substance is controlled under drug control legislation; in Lithuania it is controlled under 
medicines legislation; and in the United Kingdom it is controlled by NPS legislation. In addition, 
isotonitazene is controlled under medicines legislation in Norway. 
It is unknown if isotonitazene is controlled in China, from where at least some of the substance on the 
European market appears to have been sourced. 
COVID-19 pandemic 
The impact of the ongoing COVID-19 pandemic on the manufacture, trafficking, distribution and use 
of isotonitazene is currently unknown. Based on previous experiences with disruptions to the illicit 
opioid markets in Europe and the United States, it is conceivable that, should there be a reduced 
availability of established illicit opioids such as heroin and fentanyl and its derivatives in Europe, then 
criminal groups, as well as people who use opioids, especially high-risk opioid users, may substitute 
for these substances a range of other substances, including 2-benzylbenzimidazole opioids such as 
isotonitazene. These changes may be geographically localised or broader; they may also be single 
‘one-off’ events, or short-lived or longer-lasting changes. Similar to the recent experience with highly 
potent fentanyl derivatives, such as acryloylfentanyl and carfentanil, such changes to the drug market 
may increase the risk of life-threatening poisoning, as, currently, there is little to no experience with 
the use of isotonitazene (e.g. how to dose the substance and the effects it can cause); in some cases 
such substitution could manifest as outbreaks of poisoning. These risks will be especially high in the 
case of people who obtain isotonitazene from street-level illicit opioid markets and who are unlikely to 
be aware that they are using the substance. 
Conclusion 
Isotonitazene (N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-
ethanamine) belongs to the 2-benzylbenzimidazole group of opioid analgesics. This group includes 
etonitazene and clonitazene, both of which are under international control. Although isotonitazene 
was first synthesised in the mid-1950s, no additional reports relating to the substance could be found 
until its identification on the illicit drug market in 2019. 
The available information suggests that isotonitazene acts as a potent narcotic opioid analgesic. 
Similar to other opioid analgesics, the most serious acute risk arising from the use of isotonitazene is 
likely to be from respiratory depression, which can lead to apnoea, respiratory arrest and death. 
Naloxone is expected to work as an antidote to poisoning caused by isotonitazene. 
Isotonitazene has been available in Europe since at least April 2019 and has been identified in six 
Member States (Belgium, Estonia, Germany, Latvia, Sweden and the United Kingdom). Law 
enforcement seizures have been reported by three Member States (Estonia, Latvia and Sweden). The 
most recent identification of isotonitazene reported to the EMCDDA was from a seizure made in 
January 2020. 
As isotonitazene has emerged on the drug market in Europe only recently, it is important to note that 
its presence on the drug market and as the cause of serious adverse events may be undetected 
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because the substance is not routinely screened for in some laboratories. In addition, the ongoing 
COVID-19 pandemic may have reduced the capacity of early warning systems to detect and report 
events involving isotonitazene. 
It appears that at least some of the isotonitazene on the market in Europe has been supplied from 
China. Isotonitazene is sold online as a powder in wholesale and small amounts; it is also sold as 
ready-to-use nasal sprays. In addition, isotonitazene is sold on the illicit drug market, including, it 
appears, on street-level opioid markets. Based on the limited information, it is presumed, but not 
confirmed, that isotonitazene is being injected intravenously by high-risk opioid users in some parts of 
Europe. 
Isotonitazene can be administered in a range of ways, including orally, intranasally, by smoking or 
vaporising and by injection. 
A total of two deaths involving isotonitazene have been reported to the EMCDDA by two Member 
States (Germany and the United Kingdom), although few additional details are currently available on 
these cases. Deaths have also been reported in Canada (3 cases) and the United States (18 cases). 
Of the cases in the United States, at least some of the individuals were high-risk drug users and 
included people who had a history of injecting illicit opioids such as heroin. Polydrug use, especially 
use of two or more CNS depressants (which increases the risk of life-threatening respiratory 
depression), was also common in these individuals. 
There is no specific information on the social risks posed by isotonitazene. As isotonitazene acts as 
an opioid analgesic, it is possible that any such risks may have some similarities with those 
associated with the use of established illicit opioids, such as heroin or fentanyl and its derivatives. 
There is no information on whether or not criminal groups are involved in the manufacture, trafficking 
and distribution of isotonitazene within Europe. The impact of the ongoing COVID-19 pandemic on the 
manufacture, trafficking, distribution and use of isotonitazene is also currently unknown. Based on 
previous experiences with disruptions to the illicit opioid markets, it is conceivable that, should the 
availability of established illicit opioids such as heroin and/or fentanyl and its derivatives be reduced in 
Europe, then criminal groups, as well as people who use opioids, especially high-risk opioid users, 
may substitute for these substances a range of other substances, including 2-benzylbenzimidazole 
opioids such as isotonitazene. Such changes may increase the risk of life-threatening poisoning, as, 
currently, there is little to no experience with the use of isotonitazene (such as doses and effects). 
These risks will be especially high in the case of people who obtain isotonitazene from street-level 
illicit opioids markets and who are unlikely to be aware that they are using the substance. The 
Committee notes that, both for isotonitazene, as well as for opioids in general, a high level of vigilance 
is needed to ensure early detection, reporting, assessment, and response measures to changes in 
the drug markets relating to the pandemic that may have a high impact on public health. 
The Committee notes that while the available information on isotonitazene indicates that it is a potent 
opioid analgesic, overall there is limited information available on its pharmacology, toxicology, abuse 
liability and dependence-producing potential. Additional information may emerge with later studies but 
ideally would have been available in this assessment. The Committee notes that, to strengthen early 
warning, preparedness and response activities within the EU, such studies should be undertaken 
systematically prior to risk assessment. 
There is no information on the actual chemical precursors or manufacturing methods used to 
synthesise the isotonitazene that has been identified on the drug market in Europe. Although the 
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synthetic routes reported in the scientific literature involve several steps, depending on precursor 
availability, they are straightforward and make use of common manufacturing equipment. The starting 
materials for either synthetic route are readily available. The multi-step production of isotonitazene 
requires a basic knowledge of and experience in synthetic organic chemistry.  
Based on the available information, it appears that isotonitazene is not an active substance in any 
medicinal product for human use or in any veterinary medicinal product in Europe. However, although 
unlikely, the use of isotonitazene as an active substance in medicinal products prepared 
extemporaneously or in investigational medicinal products cannot be excluded in some Member 
States. There is currently no information suggesting that isotonitazene is used for legitimate purposes 
other than research or forensic applications. 
Isotonitazene is not listed for control in the Single Convention on Narcotic Drugs, 1961, nor in the 
Convention on Psychotropic Substances, 1971. Isotonitazene is not currently under assessment by 
the United Nations system. 
The available information would suggest that the consumption of isotonitazene causes harm to health 
associated with its acute toxicity and abuse liability or dependence-producing potential. This harm to 
health is considered life-threatening because it is likely to cause death. In addition, there is a potential 
for severe physical and mental impairment and a significant spread of diseases, including the 
transmission of blood-borne viruses. These effects, including dependence, are comparable to those of 
other opioid analgesics that are under international control, such as morphine, fentanyl and the 
closely related substance etonitazene. 
Four Member States (Estonia, Latvia, Poland and Sweden) control isotonitazene under drug control 
legislation. Two Member States (Lithuania and the United Kingdom) and Norway control isotonitazene 
under other legislation. 
As for any NPS, many of the questions related to isotonitazene that are posed by the lack of data on 
the risks to individual health, risks to public health and social risks could be answered through further 
research. Areas where additional information would be important include studies on epidemiology 
(frequency and patterns of use, including studies that examine the groups of people who use 
isotonitazene and risk behaviours); the market; chemical profiling; extended pharmacological profiling; 
metabolic pathways; behavioural effects; acute and chronic toxicity; the potential interaction between 
isotonitazene and other substances; the abuse liability and dependence-producing potential; and the 
public health and social risks associated with its use. 
The Committee notes that a decision to control isotonitazene has the potential to bring with it both 
intended and unintended consequences. Potential intended consequences include reduced levels of 
availability and ultimately use. This may reduce the health and social risks and consequences arising 
from the use of isotonitazene. It is important to recognise that a potential unintended consequence of 
control may be the manufacture and availability of other substances, including the emergence of other 
compounds from the 2-benzylbenzimidazole group of opioids. The implementation of control 
measures may also lead to the criminalisation of those who continue to use this substance, with the 
possible attendant risks of socioeconomic stigmatisation and marginalisation. 
Finally, the Committee notes that it is important to continue to collect accurate information on 
isotonitazene and to disseminate it to people who use the substance, as well as to practitioners, 
policymakers and decision-makers.  
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ANNEX 1 
Purpose 
The purpose of this technical report to provide an analyses of the available information on N,N-
diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (commonly 
known as isotonitazene), an opioid analgesic that has recently emerged on the drug market in 
Europe, to support a risk assessment of the substance that has been requested by the European 
Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). 
Parts of this report were prepared under an EMCDDA contract (ref. CT.20.SAS.0017.1.0). 
Statement regarding the United Kingdom 
The reference period for this technical report includes 2019 and 2020 (up to the time of writing). The 
United Kingdom left the European Union as of 1 February 2020. However, during the transitional 
period, the United Kingdom continues to participate in the European Union Early Warning System on 
new psychoactive substances. Unless stated otherwise, for the purpose of this report, the term 
‘Member States’ shall include the United Kingdom. 
Information sources 
The information in this technical report is derived from: 
§ Information reported by the Member States, Turkey, and Norway to the EMCDDA and 
Europol in accordance with the requirements of Article 5a and Article 5b of Regulation (EC) 
No 1920/2006 (as amended). 
§ Information reported by the European Medicines Agency (EMA), the European Chemicals 
Agency (ECHA), the European Centre for Disease Prevention and Control (ECDC), and the 
European Food Safety Authority (EFSA) to the EMCDDA in accordance with the 
requirements of Article 5b of Regulation (EC) No 1920/2006 (as amended). 
§ A review of the benzimidazole opioids commissioned by the EMCDDA (CT.20.SAS.0017.1.0). 
§ Information collected by the EMCDDA through searches of open source information, including 
the scientific and medical literature, patents, official reports, grey literature, online drug 
discussion forums and related websites, and online vendors selling isotonitazene. 
Technical report on N,N-diethyl-2-[[4-(1-
methylethoxy)phenyl]methyl]-5-nitro-1H-
benzimidazole-1-ethanamine (isotonitazene) 
 
RISK ASSESSMENT REPORT I Isotonitazene 
20 
Search strategy 
Literature searches used both chemical structure and textual queries in online databases; searches 
were conducted in March 2020. The retrieved publications were then scanned for additional relevant 
references (snowballing technique). 
SciFinder® was searched by exact structure-based search. PubMed and Web of Science were 
searched for ‘isotonitazene’ and the IUPAC name of this compound stated in this document. The 
references were screened for relevance and included in the review where appropriate. Additional 
references were gathered from the sources mentioned in the collected papers. 
Terminology and definitions 
The terminology and definitions used in this technical report are based on those used for the 
operation of the EU Early Warning System on new psychoactive substances, including those related 
to relevant internal EMCDDA processes. They can be accessed at: 
http://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance%20Note%201-
%20Terminology%20and%20definitions.pdf 
Unless otherwise indicated, the terms and definitions are for operational use only and do not have 
legal meaning. They may differ from those used in other settings and by other organisations 
(EMCDDA, 2019). 
Technical report prepared by 
Michael Evans-Brown (EMCDDA), István Ujváry (iKem BT), Joanna De Morais (EMCDDA), Rachel 
Christie (EMCDDA), Anabela Almeida (EMCDDA), Rita Jorge (EMCDDA), Ana Gallegos (EMCDDA), 
Roumen Sedefov (EMCDDA) 
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1. Summary 
During the mid-1950s, attempts to develop better and safer opioid analgesics led to the discovery of a 
series of 2-benzylbenzimidazole compounds with levels of analgesic potency several orders of 
magnitude higher than that of morphine. This group of structurally distinct opioid analgesics includes 
isotonitazene, the subject of this technical report, as well as etonitazene and metonitazene which are 
closely related homologues, and clonitazene. Both etonitazene and clonitazene are controlled under 
the United Nations Single Convention on Narcotic Drugs of 1961 (ECAPD, 1961; UNODC, 2019a) 
Although isotonitazene was first synthesised in the mid-1950s (Hoffmann et al., 1959; Hoffmann et al. 
1960; Hunger et al., 1960b), no additional reports related to the substance could be found until its 
identification on the illicit drug market in 2019 (Blanckaert et al., 2020; EMCDDA, 2020a; Ujváry, 
2020).  
In Europe, isotonitazene is monitored as a new psychoactive substance by the EMCDDA in 
accordance with Council Framework Decision 2004/757/JHA (as amended) and Regulation (EC) No 
1920/2006 (as amended) (EMCDDA, 2020a). The substance has been available on the drug market 
in Europe since at least April 2019. As isotonitazene has only recently emerged on the drug market, 
there is limited information on the substance. In particular, formal epidemiological studies have not 
been conducted, which limits understanding of the frequency and patterns of use of isotonitazene. As 
of 6 May 2020, isotonitazene is the only substance from the 2-benzylbenzimidazole series of opioid 
analgesics to be notified to the EMCDDA (2). 
As isotonitazene has only recently emerged on the drug market in Europe, it is important to note that 
its presence on the market and as the cause of serious adverse events (such as from acute 
poisonings presenting to hospital emergency rooms and medico-legal death investigations) may be 
undetected since the substance is not routinely screened for in some laboratories. An additional issue 
is that concentrations of isotonitazene in biological samples are typically low to sub-nanogram per 
millilitre which highlights a need for increased analytical sensitivity when testing for the substance. It is 
also important to note that, in some settings, the ongoing COVID-19 pandemic caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ECDC, 2020; EMCDDA, 2020b; WHO, 
2020) may have reduced the capacity of early warning systems, including forensic science and 
toxicology laboratories, to detect and report events involving isotonitazene. 
As of 28 March 2020, the EMCDDA has received reports that isotonitazene has been identified in six 
Member States: Belgium, Estonia, Germany, Latvia, Sweden, and the United Kingdom. These 
detections relate to police seizures reported by Estonia, Germany, and Latvia; a customs seizure 
reported by Sweden; a collected sample reported by Belgium; and biological samples from a death 
case reported by the United Kingdom. While the detected quantities are relatively small, they should 
be seen within the context of the possible high potency of isotonitazene. The most recent 
identification of isotonitazene reported to the EMCDDA is from a seizure made by police in Latvia in 
January 2020. 
Although isotonitazene has not been formally studied in humans, a study published in 2019 has 
demonstrated that it is a highly potent, full mu-opioid receptor (MOP) agonist in vitro (Blanckaert et al., 
2020), while an animal study published in 1960 has demonstrated that it has potent morphine-like 
 
(2) In accordance with Council Framework Decision 2004/757/JHA (as amended) and Regulation (EC) No 1920/2006 (as 
amended).  
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centrally-mediated analgesic effects (Hunger et al., 1960b). Due to its lipophilicity, isotonitazene is 
expected to be rapidly absorbed and readily cross the blood-brain barrier. Taken together, this 
information strongly suggests that isotonitazene will act as an opioid analgesic in humans. The major 
pharmacological effects of opioid analgesics are due to their activation of opioid receptors, and, in 
particular, the mu-opioid receptor. Besides their analgesic properties, a notable feature associated 
with opioid analgesics is that they cause dose-dependent respiratory depression (slowing down of 
breathing), in which overdose can be life-threatening. Other additional pharmacological effects include 
miosis, sedation, bradycardia, hypothermia, constipation, physical dependence, and changes in mood 
such as euphoria (Herz, 1993; Kieffer, 1999; Pasternak and Pan, 2013; Pattinson, 2008; Romberg et 
al., 2003).  
Based on the available pharmacological information, and similar to other opioid analgesics, the most 
serious acute risk from the use of isotonitazene in humans is likely to be from respiratory depression, 
which can lead to apnoea, respiratory arrest, and death (Pattinson, 2008; Romberg et al., 2003; White 
and Irvine, 1999). Compounding this risk is that isotonitazene is the first of the 2-benzylbenzimidazole 
opioids to be identified on the drug market in recent years, and users have no experience with this 
group of opioids (such as how to dose the substance and the effects it causes) which may increase 
the risk of accidental overdose and cause life-threatening poisoning. This risk will be especially high if 
users are unaware that they are using isotonitazene, which may be the case when it is sold at street-
level on the illicit opioid market. While clinical experience in treating poisonings caused by 
isotonitazene have not been reported, based on the pharmacological profile of the substance, 
naloxone is expected to work as an antidote and reverse respiratory depression (Boyer, 2012; Kim 
and Nelson, 2015). There is no information on the chronic health effects of isotonitazene. Similar to 
other opioids, the chronic health risks might share some similarities to those seen with established 
illicit opioids, such as heroin and fentanyl; this may include dependence.  
In Europe, a total of two deaths involving isotonitazene have been reported to the EMCDDA by 
Germany and the United Kingdom; few additional details are currently available on these cases. 
Deaths have also been reported in Canada (3 cases) (Toxicovigilance Canada, 2019) and the United 
States (18 cases) (Krotulski et al., 2020). In all cases, the role of isotonitazene in the deaths is 
unknown. In the deaths reported from the United States, at least some of the individuals were high 
risk drug users and included people who had a history of injecting opioids such as heroin. Polydrug 
use, especially use of two or more central nervous system (CNS) depressants (which increases the 
risk of life-threatening respiratory depression (US FDA, 2016)) was also common in these individuals 
(Krotulski et al., 2020). 
There is limited information on the manufacture, trafficking, distribution, and use of isotonitazene in 
Europe. It appears that at least some of the isotonitazene on the market has been produced by 
chemical companies based in China. Although the size and scale of the operations are unknown, 
isotonitazene is sold online as a powder in wholesale and small amounts; it is also sold as ready to-
use nasal sprays. Isotonitazene may also have been sold on the illicit opioid market at street-level in 
at least two Member States in Europe (Estonia and Latvia). In what appears to be a small number of 
cases, isotonitazene may be deliberately sought after by some users (such as people who self-
experiment with psychoactive substances (‘psychonauts’)); others, such as those that purchase it on 
street-level illicit opioids markets, may be unaware that they are using the substance which presents 
an inherent risk to the individuals.  
There is no information on whether or not criminal groups are involved in the manufacture, trafficking, 
and distribution of isotonitazene within Europe (EMCDDA, 2020a). The impact of the ongoing COVID-
19 pandemic (ECDD, 2020; EMCDDA, 2020b; WHO, 2020) on the manufacture, trafficking, 
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distribution, and use of isotonitazene is also currently unknown. Based on previous experiences with 
disruptions to the illicit opioid markets (Ciccarone, 2019; EMCDDA, 2011; EMCDDA, 2012; Mars et 
al., 2019), it is conceivable, that, should the availability of established illicit opioids, such as heroin 
and/or fentanyl and its derivatives, be reduced in Europe, then criminal groups, as well as people who 
use opioids, especially high risk opioid users, may substitute these substances for a range of other 
substances, including 2-benzylbenzimidazole opioids such as isotonitazene. These changes may be 
geographically localised or broader, they may also be single ‘one off’ events, or short-lived, or longer 
lasting changes. Similar to the recent experience with highly potent fentanyl derivatives, such as 
acryloylfentanyl and carfentanil, such changes to the drug market may increase the risk of life-
threatening poisoning, as, currently, there is little to no experience with the use of isotonitazene (such 
as doses and effects); in some cases such substitution could manifest as outbreaks of poisoning 
(EMCDDA, 2018; Evans-Brown and Sedefov, 2018; Ujváry et al., 2017). These risks will be especially 
high in the case of people who obtain isotonitazene from street-level illicit opioids markets who are 
unlikely to be aware that they are using the substance. 
There is no information on the social harms that may be caused by isotonitazene. Despite this, it is 
likely that some of the risks are similar to those associated with the use of established illicit opioids, 
such as heroin and fentanyl. 
Based on the available information, it appears that isotonitazene is not an active substance in a 
medicinal product for human use or in a veterinary medicinal product in Europe. However, although 
unlikely, the use of isotonitazene as an active substance in medicinal products prepared 
extemporaneously or in investigational medicinal products cannot be excluded in some Member 
States (EMCDDA, 2020a). There is currently no information that suggests isotonitazene is used for 
legitimate purposes other than research or forensic application (EMCDDA, 2020a). 
Isotonitazene is not controlled under the United Nations Single Convention on Narcotic Drugs, 1961, 
as amended by the 1972 Protocol, nor the Convention on Psychotropic Substances of 1971 (‘United 
Nations system’) (UNODC, 2019a; UNODC, 2019b). Isotonitazene has not been subject to 
assessment nor is it currently under assessment by the United Nations system (EMCDDA, 2020a). In 
Europe, isotonitazene is subject to restrictive measures in six Member States: in Estonia, Latvia, 
Poland, and Sweden the substance is controlled under drug control legislation; in Lithuania it is 
controlled under medicines legislation; while in the United Kingdom it is controlled by new 
psychoactive substance legislation. In addition, isotonitazene is controlled under medicines legislation 
in Norway. It is unknown if isotonitazene is controlled in China, where at least some of the substance 
on the European market has been sourced from (EMCDDA, 2020a). 
2. Chemical and physical properties, methods and the precursors 
used for manufacture or extraction 
2.1 Background 
During the mid-1950s, attempts to develop better and safer opioid analgesics led to the discovery of a 
series of 2-benzylbenzimidazole compounds with levels of analgesic potency several orders of 
magnitude higher than morphine. This group of structurally distinct analgesics was invented by the 
pharmaceutical research laboratories of the Swiss chemical company CIBA Aktiengesellschaft 
(Hunger et al., 1957; Gross and Turrian, 1957; Hunger et al., 1960a,b). Though this particular 
research effort did not yield any marketed analgesic medicine, the bold departure from the morphine 
structure demonstrated that high levels of opioid activity could be achieved by substances structurally 
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less complex than morphine and by substances bearing no structural resemblance to the 
phenanthrene skeleton of morphine. This new series of compounds included N,N-diethyl-2-[[4-(1-
methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene), the subject of 
this technical report, and the closely related homologues, etonitazene (3) and metonitazene (4), as 
well as clonitazene (5). Etonitazene and clonitazene are the most intensively studied compounds from 
the series (Ujváry, 2020). Shortly after their invention, and based on a notification by the United 
States Government, both etonitazene and clonitazene were controlled under the original Schedule I 
list of the United Nations Single Convention on Narcotic Drugs of 1961 because of their ability to 
produce morphine-like effects, to suppress abstinence phenomena of a known morphine addiction, as 
well as to sustain morphine addiction (ECAPD, 1961; Ujváry, 2020). 
Although this series of compounds was highlighted by the chemist Alexander T. Shulgin more than 40 
years ago as a ‘fertile field for the search for heroin substitutes that can be domestically synthesized 
and are potent at levels that would encourage illicit investigation’ (Shulgin, 1975), until 2019, when 
isotonitazene was first identified on the illicit drug market, only etonitazene had been sporadically 
encountered on the drug market: first in a ‘brownish looking powder‘ in Milan, Italy, in 1966 
(Branderberger, 1974), then in Germany in 1987 [cited by Sorokin et al., 1999], in Russia in 1998 and 
1999 (Sorokin, 1999; Sorokin et al., 1999), and, finally, in the United States in 2003 (Reavy, 2003; 
Morris, 2009). 
Although isotonitazene was one of 2-benzylbenzimidazole compounds reported in patents and in the 
original study on this group of substances (Hoffmann et al., 1959; Hoffmann et al. 1960; Hunger et al., 
1960b), no additional reports related to isotonitazene could be found until its identification on the illicit 
drug market in 2019 (Blanckaert et al., 2020; EMCDDA, 2020a; Ujváry, 2020). As of 6 May 2020, 
isotonitazene is the only substance from the 2-benzylbenzimidazole series of opioid analgesics to be 
identified on the European drug market and notified to the EMCDDA through the European Union 
Early Warning System on new psychoactive substances (6). 
2.2 Names and chemical structure 
Isotonitazene belongs to the 2-benzylbenzimidazole group of opioid analgesics. In particular, it is a 5-
nitro-2-benzylbenzimidazole. This group also includes the closely related homologues, etonitazene 
and metonitazene, as well as clonitazene.  
Isotonitazene differs from etonitazene and metonitazene in the substitution at the para-position of the 
benzyl moiety, which is an isopropoxy group in isotonitazene, an ethoxy group in etonitazene, a 
methoxy group in metonitazene. Isotonitazene differs from clonitazene by replacement of the chloro 
 
(3) IUPAC name: N,N-diethyl-2-[(4-ethoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
(4) IUPAC name: N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
(5) IUPAC name: N,N-diethyl-2-[(4-chlorophenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine  
(6) In accordance with Council Framework Decision 2004/757/JHA (as amended) and Regulation (EC) No 1920/2006 (as 
amended). 
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halogen atom with the ethereal isopropoxy group. The chemical structure and molecular properties of 
these compounds are provided in Figure 1 (7). 
FIGURE 1 
Chemical structure and molecular properties of isotonitazene, etonitazene, metonitazene, and 
clonitazene. 
Isotonitazene Etonitazene Metonitazene Clonitazene 
    
Molecular formula: 
C23H30N4O3 
Molecular weight: 
410.51 
Monoisotopic mass: 
410.2318 
logP: 4.85 
miLogP: 5.08 
TPSA: 76.11 Å2 
Molecular formula: 
C22H28N4O3 
Molecular weight: 
396.48 
Monoisotopic mass: 
396.2161 
logP: 4.85 
miLogP: 4.71 
TPSA: 76.11 Å2 
Molecular formula: 
C21H26N4O3 
Molecular weight: 
382.46 
Monoisotopic mass: 
382.2005 
logP: 4.086 
miLogP: 4.34 
TPSA: 76.11 Å2 
Molecular formula: 
C20H23ClN4O2 
Molecular weight: 
386.88 
Monoisotopic mass: 
386.1510 
logP: 4.85 
miLogP: 4.96 
TPSA: 66.88 Å2 
 
The octanol/water distribution coefficients logP (8) or miLogP were calculated by Molinspiration 
property engine v2018.10 (9) and StarDrop® Version 6.6 software, (10) respectively. The topological 
polar surface area (TPSA) (11) was calculated by StarDrop® Version 6.6 software. 
Common name: 
Isotonitazene 
 
(7) Another closely related substance is the n-propoxy isomer of isotonitazene, known as protonitazene (N,N-diethyl-2-[(4-
propoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine). Protonitazene differs from isotonitazene in the substitution at 
the para-position of the benzyl moiety, which is an isopropoxy group in isotonitazene and a propoxy group in protonitazene. 
Information of the pharmacology of pronitazene can be found in Hunger et al., (1960b) (compound XLIII in Table I); briefly 
protonitazene was around 200 times more potent than morphine as an antinociceptive drug in mice, and, after etonitazene and 
isotonitazene, was the third most potent substance in the series (Hunger et al., 1960b). 
 
As discussed in section 2.5, GC-MS analysis of isotonitazene and protonitazene will result in very similar mass spectrometry 
fragmentation patterns. The ability to distinguish between both isomers requires the use of analytical reference standards, 
access to reference spectra for both substances, or additional analytical methods.  
(8) LogP is the logarithm of the partition of a substance between an apolar organic solvent, typically n-octanol, and water. It is 
used as a measure of lipophilicity of a substance. For fentanyl, calculated logP values are 3.89 (StarDrop) and 3.79 
(Molinspiration), while the measured logP = 4.05 (Hansch et al., 2005). 
(9) https://www.molinspiration.com/cgi-bin/properties 
(10) Optibrium Ltd, Cambridge, UK. 
(11) Topological polar surface area (TPSA) is a calculated measure the surface area occupied by nitrogen and oxygen atoms 
and the polar hydrogen atoms attached to them. For drugs acting on the central nervous system a TPSA is usually <90 Å2. For 
fentanyl, the calculated TPSA = 23.6 Å2. 
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Systematic (IUPAC) name: 
N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
Other chemical names: 
N,N-diethyl-2-[2-({4-[(propan-2-yl)oxy]phenyl}methyl)-5-nitro-1H-benzimidazol-1-yl]ethan-1-amine 
 N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine 
N,N-diethyl-2-[2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl]ethanamine 
N,N-diethyl-2-[2-[(4-isopropoxyphenyl)methyl]-5-nitro-benzimidazol-1-yl]ethanamine 
N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
N,N-diethyl-2-[5-nitro-2-[(4-propan-2-yloxyphenyl)methyl]benzimidazol-1-yl]ethanamine 
1-[2-(diethylamino)ethyl]-2-(p-isopropoxybenzyl)-5-nitrobenzimidazole 
Street names: 
‘iso’, 'Toni’ 
Chemical Abstracts Service (CAS) registry numbers: 
14188-81-9 free base 
119276-00-5 hydrochloride salt 
IUPAC International Chemical Identifier Key (InCHI Key): 
OIOQREYBGDAYGT-UHFFFAOYSA-N 
Simplified Molecular-Input Line-Entry System (SMILES): 
CCN(CC)CCN1C(CC2=CC=C(OC(C)C)C=C2)=NC3=CC([N+]([O-])=O)=CC=C31 
2.3 Physical properties 
Both the free base and salts of isotonitazene are solids. 
The measured melting point for isotonitazene hydrochloride salt is 172–173 °C (Hoffmann et al., 
1960; Hunger et al., 1960b). 
Isotonitazene is lipophilic (calculated logP = 4.85). 
Isotonitazene, as both the freebase and the hydrochloride salt, is soluble in methanol (NPS 
Discovery, 2019; Blanckaert et al., 2020) and in dimethyl sulfoxide (DMSO) (Blanckaert et al., 2020). 
Although no experimental data are available, the salts of isotonitazene, similar to etonitazene, are 
expected to be sufficiently water-soluble for injectable administration of effective doses. 
To date, seizures and collected samples containing isotonitazene reported to the EMCDDA have 
been in brown, yellow, and white powders. In addition, isotonitazene has also been identified in liquid 
form. Identifications of isotonitazene reported to the EMCDDA include both the free base and the 
hydrochloride salt. 
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No studies have examined the stability and reactivity of isotonitazene. As a base, the substance 
readily forms salts with inorganic or organic acids. Chemical reducing agents are expected to convert 
the nitro group into an amino group. For metabolic conversions, see Section 4.4 on pharmacokinetics. 
2.4 Methods and chemical precursors used for the manufacture or extraction 
There is no information on the chemical precursors or manufacturing methods used to synthesise the 
isotonitazene which has been identified on the drug market in Europe. 
Several routes have been developed for the synthesis of etonitazene-related 2-benzylbenzimidazoles 
(Hunger et al., 1957; Hunger et al., 1960a). The synthesis of isotonitazene is specifically described in 
a patent and is outlined in Figure 2 (Hoffmann et al., 1960).  
The activated chloro atom in the readily available 1-chloro-2,4-dinitrobenzene is easily displaced by 2-
diethylaminoethylamine. Regioselective reduction of the nitro function adjacent to the alkylamino 
moiety of the resultant 2,4-dinitroaniline derivative is accomplished using ammonium sulfide. 
Condensation of the obtained ortho-phenylenediamine species (12) with the imidate of 4-
isopropoxyphenylacetic acid, obtained from the corresponding cyanide, affords the final product, that 
is isotonitazene. Purification is accomplished by base-acid extraction followed by conversion of the 
free base into its hydrochloride salt. 
Although there is no information on the actual method used for the manufacture of isotonitazene that 
has been identified on the drug market, one possible approach may follow the improved method as 
described for etonitazene by Carroll et al. (1975). The authors describe the method as simple, 
producing high yields, which can be adapted to both large scale preparations and for the preparations 
of other 2-benzylbenzimidazole opioids (Carroll et al., 1975). Alternatively, alkylation by isopropyl 
bromide of a phenolic species (‘desethyletonitazene’), which was reported to be a versatile precursor 
for other homologues (Hoffmann et al., 1959; Hoffmann et al., 1960), may also be used to produce 
isotonitazene. 
 
 
 
 
 
 
 
 
 
(12) IUPAC name: N1-[2-(diethylaminoethyl]-4-nitrobenzene-1,2-diamine 
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FIGURE 2 
Synthesis of isotonitazene (Hoffmann et al., 1960). 
 
 
Analytically confirmed detections of the closely related homologue etonitazene on the illicit drug 
market in Moscow, Russia, were reported in 1998 and 1999 (Sorokin, 1999; Sorokin et al., 1999b). 
Information from one of these cases noted that the substance had been synthesised in Russia, using 
a modification of a method published by Hunger et al. (1960b). These reports also noted the 
identification of etonitazene on the illicit drug market in Germany in 1987, which also apparently used 
the synthetic route described earlier (Hunger et al., 1960b). 
Recently, a ‘one-pot’, three component synthesis producing 2-benzylbenzimidazole opioids at high 
yield has also been reported (Kim et al., 2011). 
2.5 Methods for identification and analysis 
Methods documented in the literature for the identification and analysis of isotonitazene in physical 
samples include: gas chromatography–mass spectrometry (GC-MS); Fourier transform infrared 
spectroscopy (FTIR), 1H and 13C nuclear magnetic resonance spectroscopy (NMR), Raman 
spectroscopy and ultraviolet spectroscopy; and high-performance liquid chromatography (HPLC) 
(ADEBAR, 2020; Blanckaert et al., 2020; Cayman Chemical, 2020a; Krotulski et al., 2020; NPS 
Discovery, 2019) (Table 1). Isotonitazene is available as analytical reference material (Cayman 
Chemical, 2020a). 
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TABLE 1 
Analytical methods used for the characterisation of isotonitazene in physical samples (Ujváry, 
2020). 
Analytical method Reference 
High-performance liquid chromatography NPSDiscovery, 2019 
ADEBAR, 2020 
Blanckaert et al., 2020 
Ultraviolet spectroscopy Blanckaert et al., 2020 
Cayman Chemical, 2020a 
Infrared spectroscopy ADEBAR, 2020 
Blanckaert et al., 2020 
Raman spectroscopy ADEBAR, 2020 
1H NMR spectroscopy ADEBAR, 2020 
Blanckaert et al., 2020 
13C NMR spectroscopy ADEBAR, 2020 
Blanckaert et al., 2020 
Mass spectrometry  NPSDiscovery, 2019 
ADEBAR, 2020 
Blanckaert et al., 2020 
Cayman Chemical, 2020a 
Methods have also been documented in the literature for the identification of isotonitazene in 
biological samples, which include HPLC and liquid chromatography with tandem mass spectrometry 
(LC-MS/MS) (Krotulski et al., 2020). It is important to highlight the need for increased analytical 
sensitivity when testing for isotonitazene in biological samples following quantitative results from 
blood and urine samples which were in some cases in the sub-nanogram per millilitre range (Krotulski 
et al., 2020).  
It is important to note that GC-MS analysis of isotonitazene and the n-propoxy isomer of 
isotonitazene, protonitazene (13), will result in very similar mass spectrometry fragmentation patterns. 
The ability to distinguish between both isomers requires the use of analytical reference standards, 
access to reference spectra for both substances, or additional analytical methods. Protonitazene is 
available as analytical reference material (Cayman Chemical, 2020b). 
2.6 Dosage regimens 
Information on the dosage regimens (14) used for isotonitazene is limited. Isotonitazene (15) can be 
administered orally as a powder, as tablets, or as a solution; it can also be administered intranasally 
 
(13) IUPAC name for protonitazene: N,N-diethyl-2-[(4-propoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine 
(14) Dosage regimen: is information on the formulation (dosage form), route of exposure, as well as the schedule of doses of a 
new psychoactive substance, including the amount taken each time, time between doses, and the duration of use.  
(15) It may be assumed that seizures contain isotonitazene in a salt form, which is water-soluble. There is, however, no 
information on the aqueous solubility of the salt. 
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or sublingually via spray or snorted (insufflated); inhaled by vaporising e-liquid solutions (‘vaping’); 
inhaled by smoking or vaporising the ‘free base’; and injected. 
Given the illicit nature of the trade in isotonitazene, the composition of physical samples (law 
enforcement seizures and collected samples) is likely to vary over time and place, as well as based 
on the specific location in the drug supply chain in which the sample was obtained from (for example, 
from the manufacturer, wholesaler, retailer, or at street-level Illicit opioid markets). In Europe, 
isotonitazene has been seized by law enforcement predominately in powder form; in two cases it has 
also been seized as a liquid. Information on the amount of isotonitazene present in seized powders 
(chemical purity) has not been reported, however information from police seizures in Estonia noted 
the presence of ‘common sugars’ in at least some of the samples (not specified further); while one 
seizure made by police in Latvia also contained fentanyl. Results from the analysis of a collected 
sample of isotonitazene in powder form that was purchased from an online vendor noted that 
isotonitazene was the only substance present in the sample and no impurities were identified. The 
study concluded that the sample was the hydrochloride salt of the substance in high purity (Section 
5.3) (Blanckaert et al., 2020). In Canada, isotonitazene has been identified both in powder form as 
well as in falsified (fake) opioid analgesic medicines (DSPM, 2020). In the latter case, this includes 
fake Dilaudid® tablets (hydromorphone hydrochloride) that were seized in February 2020 (Halifax 
Police, 2020). 
Based on the limited information reported to the EMCDDA from police seizures, it is presumed, but 
not confirmed, that isotonitazene is being injected intravenously by high risk opioid users in some 
parts of Europe. Although the drug situation is different from Europe, information from a case series of 
18 deaths with confirmed exposure to isotonitazene in the United States noted that at least some of 
the individuals were high risk drug users and included people who had a history of injecting opioids 
such as heroin. In addition, isotonitazene was identified along with one or more other psychoactive 
substances (controlled drugs and new psychoactive substances) in all the deaths, which suggests 
that polydrug use was common in these individuals (Krotulski et al., 2020) (Section 6.2.2). 
While formal epidemiological studies have not been performed, the small number of anecdotal self-
reported experiences on user websites suggest, that, similar to other opioid analgesics, the dosage 
regimens used for isotonitazene can differ within and between individuals. It is not possible to 
currently discern typically dosage regimens. These also depend on the tolerance of the user, the use 
of other drugs, and the desired effects. Furthermore, the purity, amount and/or composition of the 
substance ingested are not typically known by the user. In addition, the actual composition of the 
substance may differ over time and place. Nonetheless, a range of dosage regimens, including 
differing routes of administration (such as intravenous injection and nasal insufflation by spray), 
formulations (dosage forms), as well as the schedule of doses of isotonitazene, including the amount 
taken each time, time between doses, and the duration of use, have been noted on user websites; 
polydrug use has also been noted as part of some of these self-reported experiences.  
3. Legitimate use 
3.1 Summary 
Based on the available information, it appears that isotonitazene is not an active substance in a 
medicinal product for human use or in a veterinary medicinal product in Europe. However, although 
highly unlikely, the use of isotonitazene as an active substance in medicinal products prepared 
extemporaneously or in investigational medicinal products cannot be excluded in some Member 
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States (EMCDDA, 2020a). There is currently no information that suggests isotonitazene is used for 
legitimate purposes other than research or forensic application.  
3.2 Medical use 
Based on information from the European Medicines Agency for the initial report (EMCDDA, 2020a), it 
appears that isotonitazene is not an active substance in: 
§ a medicinal product for human use or in a veterinary medicinal product that has obtained a 
marketing authorisation in accordance with Directive 2001/83/ EC of the European Parliament 
and of the Council, Directive 2001/82/EC of the European Parliament and of the Council or 
Regulation (EC) No 726/2004 of the European Parliament and of the Council;  
§ a medicinal product for human use or in a veterinary medicinal product that is the subject of 
an application for a marketing authorisation;  
§ a medicinal product for human use or in a veterinary medicinal product whose marketing 
authorisation has been suspended by the competent authority. 
In addition, it appears that isotonitazene is not an active substance in the following, although the 
information, especially in relation to use in extemporaneously prepared products, is unknown in some 
cases: 
§ an unauthorised medicinal product for human use in accordance with Article 5 of Directive 
2001/83/ EC or in a veterinary medicinal product prepared extemporaneously by a person 
authorised to do so under national law in accordance with point (c) of Article 10(1) of Directive 
2001/82/EC;  
§ an investigational medicinal product as defined in point (d) of Article 2 of Directive 
2001/20/EC of the European Parliament and of the Council. 
3.3 Industrial, commercial, and scientific use 
Isotonitazene is used as an analytical reference material in clinical and forensic case work as well as 
scientific research. There is currently no information that suggests isotonitazene is used for other 
legitimate purposes.  
As part of the initial report process, the European Chemical Agency (ECHA) and European Food 
Standard Authority (EFSA) reported to the EMCDDA that isotonitazene did not retrieve any results in 
their information systems (EMCDDA, 2020a). 
4. Pharmacological and toxicological properties 
4.1 Summary 
There is limited information on the pharmacological properties of isotonitazene. Although 
isotonitazene has not been formally studied in humans, a study published in 2019 has demonstrated 
that it is a highly potent, full mu-opioid receptor (MOP) agonist in vitro (Blanckaert et al., 2020), while 
an animal study published in 1960 has demonstrated that it has potent morphine-like centrally-
mediated analgesic effects (Hunger et al., 1960b). Due to its lipophilicity, isotonitazene is expected to 
be rapidly absorbed and readily cross the blood-brain barrier. Taken together, this information 
strongly suggests that isotonitazene will act as an opioid analgesic in humans. The major 
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pharmacological effects of such opioid analgesics, including their analgesic activity, are due to their 
activation of the MOP receptor. Besides their analgesic properties, a notable feature associated with 
opioid analgesics is that they cause dose-dependent respiratory depression, in which overdose can 
be life-threatening. Other additional pharmacological effects include miosis, sedation, bradycardia, 
hypothermia, constipation, physical dependence, and changes in mood such as euphoria (Herz, 
1993; Kieffer, 1999; Pasternak and Pan, 2013; Pattinson, 2008; Romberg et al., 2003). 
Although not formally studied, the psychological and behavioural effects of isotonitazene are likely to 
share some similarities with those commonly reported for other opioid analgesics, including: 
dizziness, drowsiness, mental confusion, incoordination, relaxation, and euphoria; at higher doses, 
sedation and profound intoxication would be expected. 
The toxicological properties of isotonitazene have not been studied. Despite the lack of experimental 
data, observations that antinociceptive potency in general correlates with acute toxicity within the 2-
benzylbenzimidazole group of opioids, including for etonitazene or metonitazene, that are both closely 
related homologues of isotonitazene, suggest that the acute toxicity of isotonitazene, at least in 
animal models, may be much greater than morphine and similar to that estimated for etonitazene or 
metonitazene. 
Based on the available information, and, similar to other opioid analgesics, the most serious acute 
health risk from isotonitazene is likely to be life-threatening respiratory depression (Pattinson, 2008; 
Romberg et al., 2003; White and Irvine, 1999). The use of isotonitazene with other central nervous 
system (CNS) depressants is likely to produce additive depressant effects which can increase the risk 
of life-threatening respiratory depression (US FDA, 2016). 
The abuse liability and dependence producing potential of isotonitazene have not been studied. 
However, etonitazene and metonitazene, both closely related homologues to isotonitazene, as well 
other members of this group, have been studied to varying degrees. Similar to other opioid 
analgesics, these studies suggest that members of the 2-benzylbenzimidazole group of opioids, 
including isotonitazene, are likely to have an abuse liability and dependence-producing potential in 
humans. 
4.1 Pharmacodynamics 
4.1.1 In vitro data 
Data on the effect of isotonitazene on MOP (μ) receptors in vitro have recently been published (Table 
2) (Blanckaert et al., 2020). The MOP receptor agonist activity in a live cell-based reporter assay of an 
isotonitazene sample purchased from an online vendor was essentially identical with that of an 
isotonitazene reference standard (Cayman Chemical, 2020a) indicating its high purity. Receptor 
activation potency (EC50) and efficacy (Emax) data show that, similar to fentanyl, isotonitazene is a 
highly potent, full MOP receptor agonist in vitro. The opioid receptor antagonist naloxone antagonised 
MOP receptor activation by isotonitazene. There are no comparative data available for etonitazene or 
metonitazene, both closely related homologues of isotonitazene, from this study. 
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TABLE 2 
Potency (EC50) and efficacy (Emax) of hydromorphone, isotonitazene reference standard (from 
Cayman Chemical (2020a)), and an isotonitazene sample (from an online vendor) in an opioid 
receptor activation assay. Data for fentanyl is also shown but from unpublished results using 
the same assay (Blanckaert et al., 2020).  
Compound EC50 (nM) Emax (%) 
Hydromorphone 26.3 (22.0–30.7) 100 (97.3–103) 
Fentanyl 18.7 (15.1–23.3) 155 (149–161) 
Isotonitazene (reference 
standard) 11.1 (9.10–13.6) 180 (174–186) 
Isotonitazene (online vendor) 12.9 (11.7–14.3) 183 (180–187) 
No information is available on any potential activity of isotonitazene at other pharmacological target. 
4.1.2 In vivo data 
Subcutaneously injected isotonitazene was 500 times more potent as morphine as an antinociceptive 
drug in the mouse tail-flick assay (radiant heat method) (Hunger et al., 1960b) (code number XLII in 
Table 3). Of the substances reported so far in this series isotonitazene was the second most active 
after etonitazene. The tail-flick assay is a useful assay for discriminating between centrally acting 
morphine-like analgesics and non-opiate analgesics (Daniel, 2016). 
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TABLE 3 
Antinociceptive potencies of isotonitazene, etonitazene and metonitazene, both closely related 
homologues to isotonitazene, as well clonitazene, relative to 5 mg/kg subcutaneously (sc) or 
25 mg/kg orally administered morphine in mice; sc injection to rats relative to 2 mg/kg 
morphine sc, and iv injection to rabbits relative to 3 mg/kg morphine iv. Potency was 
determined by measuring delay in reaction time to radiant heat stimulation of the mouse tail (tail-flick), 
by the tail pressure method in rats and by the ear-pinch reflex method in the rabbit. Codes in Arabic 
numerals refer to those in the original publications (Hunger et al., 1957; Gross and Turrian, 1957). 
The substance with a Roman numeral code is isotonitazene and is from a subsequent publication 
(Hunger et al., 1960b; Ujváry, 2020). 
 
Code 
number 
Common 
name (if any) 
  R1 R2  X        Relative potency 
     mouse rat rabbit 
  sc oral   sc   iv 
 morphine            not applicable    1   1   1    1 
8 clonitazene CH2CH3 4-Cl 5-NO2    3   5   1    10 
13 metonitazene CH2CH3 4-OCH3 5-NO2  100  15  30  200 
14 etonitazene CH2CH3 4-OCH2CH3 5-NO2 1000 1250 1000 1000 
XLII isotonitazene CH2CH3 4-OCH(CH3)2 5-NO2  500          No data 
 
4.2 Psychological and behavioural effects 
The psychological and behavioural effects of isotonitazene have not been studied. Based on the 
limited information on the pharmacological properties of isotonitazene, as well information from the 
study of etonitazene and metonitazene, and other substances from this group (Ujváry, 2020), it is 
likely that the effects of isotonitazene share some similarities with those commonly reported for other 
opioid analgesics, including: dizziness, drowsiness, mental confusion, incoordination, relaxation, and 
euphoria; at higher doses, sedation and profound intoxication would be expected. 
4.3 Safety pharmacology 
The safety pharmacology of isotonitazene has not been studied. Based on the limited information on 
the pharmacological properties of isotonitazene, as well information from the study of etonitazene and 
metonitazene, and other substances from this group, and, similar to other opioid analgesics, the most 
serious acute risk from the use of isotonitazene in humans is likely to be from dose-dependent 
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respiratory depression, which can lead to apnoea, respiratory arrest, and death (Pattinson, 2008; 
Romberg et al., 2003; White and Irvine, 1999). 
4.4 Pharmacokinetics 
The pharmacokinetics of isotonitazene has not been studied. However, a recent publication that 
describes a series of 18 death cases with confirmed exposure to isotonitazene in the United States 
identified several common metabolites from urine and blood (Krotulski et al., 2020). The proposed 
metabolic scheme is shown in Figure 3. The principal urinary metabolites were the N-dealkylated 
product, the tertiary amine affording the corresponding secondary amine derivative of isotonitazene 
(N-desethyl-isotonitazene or ‘nor-isotonitazene’; M1) and the N-dealkyl-O-dealkyl species (N-
desethyl-O-desisopropyl-isotonitazene; M3). The 5-amino metabolite (M4), arising from the reduction 
of the 5-nitro group, was detected in the majority of blood samples. Urinary metabolites M1 and M3 
appear to be most suitable for monitoring the ingestion of isotonitazene. The O-dealkylated metabolite 
M3 could also be a useful marker of etonitazene and metonitazene ingestion as well. 
FIGURE 3 
Proposed metabolism of isotonitazene (Krotulski et al., 2020) 
 
It is noted that the phenolic M2 was reported to be equipotent with morphine (Hunger et al., 1960b). 
Although the reduced amine M4 has not been reported, the 4-ethoxy analogue, a potential metabolite 
of etonitazene, is twice as potent as morphine (Hunger et al., 1960b). Nevertheless, the contribution 
of metabolites M2 and M4 to the overall effects in vivo of isotonitazene or close etonitazene 
analogues should be negligible. There are no pharmacology data on metabolites M1 and M3. 
The N-desethyl metabolite (M1) was also detected in urine and blood samples from a death case with 
confirmed exposure to isotonitazene reported by the United Kingdom (Section 5.4; Section 6.2.2) 
(EMCDDA, 2020a).  
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4.5 Toxicology 
The toxicology of isotonitazene has not been studied. However, the acute toxicity of etonitazene and 
metonitazene, both closely related homologues to isotonitazene, as well other members of this group, 
has been studied in mice and rabbits (Gross and Turrian, 1957; Ujvary, 2020). The LD50 values in 
mice, and the ‘medium lethal dose’ in rabbits with or without urethane narcosis (16) as well as 
respiratory depression in rabbits pretreated with urethane for etonitazene, metonitazene, as well as 
clonitazene are shown in Table 4. Mechanical ventilation or the respiratory stimulants nikethamide 
and bemegride counteracted respiratory depression. Of note is that pretreatment of rabbits with the 
narcotic anaesthetic urethane increased the toxicity of the compounds by several orders of 
magnitude. 
Despite the lack of experimental data, observations that antinociceptive potency in general correlates 
with acute toxicity within this group of substances suggest that toxicity of isotonitazene may be similar 
to that estimated for metonitazene or etonitazene. 
TABLE 4 
Toxic effects of selected 2-benzylbenzimidazole opioids in different laboratory animals upon 
oral (mouse) or intravenous (mouse and rabbit) administration. For rabbits, acute toxicity was 
assessed either with or without urethane-pretreatment (1.4 g/kg subcutaneous); the effect on 
respiration was studied with urethane-pretreatment (1.4 g/kg subcutaneous) (Gross and 
Turrian, 1957). 
Compound Mouse LD50 (mg/kg) Rabbit toxicity (all doses in mg/kg) 
Median lethal dose Dose 
decreasing 
respiration 
frequency by 
50% 
    iv  oral without 
urethane 
urethane 
pretreatment 
Morphine 200 1000 250 1.0 0.5 
Clonitazene 50 100 25 0.25 0.17 
Metonitazene 50 100 50 0.025 0.010 
Etonitazene 1 25 0.5 0.0025 0.0005 
Isotonitazene No data 
While no opioid antagonist was used in this particular study, subsequent experiments with isolated 
tissues (Gyang et al., 1964; Hughes et al., 1975), receptor studies in vitro (Pert and Snyder, 1973) 
and experiments in vivo (Barnett et al., 1975; Aceto et al., 1994; Achat-Mendes et al., 2009) indicated 
that opioid antagonists counteract etonitazene-induced effects. Importantly, during a human clinical 
trial, respiratory depression and coma caused by 1 mg subcutaneously administered metonitazene 
could be antagonised by prompt intravenous injection of 5 mg of the opioid antagonist nalorphine 
 
(16) Urethane (ethyl carbamate) is an narcotic anaesthetic and was used at a 1.4 g/kg subcutaneous dose in this case. 
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(Bromig, 1958). More specifically, activation of a MOP receptor preparation in vitro by isotonitazene 
was antagonised by the opioid antagonist naloxone (Blanckaert et al., 2020). 
Based on the available information for isotonitazene and related substances, and similar to other 
opioid analgesics, the most serious acute health risk from isotonitazene is likely to be respiratory 
depression, which in overdose could lead to apnoea, respiratory arrest, and death (Pattinson, 2008; 
Romberg et al., 2003; White and Irvine, 1999).  
Similarly to other opioid analgesics, the use of isotonitazene with other central nervous system (CNS) 
depressants, including other opioids, sedatives/hypnotics, alcohol, pregabalin, gabapentin, 
tranquillisers, and sedating anti-histamines, is likely to produce additive depressant effects which can 
increase the risk of life-threatening respiratory depression, arrest, and death (US FDA, 2016). 
4.6 Abuse liability and dependence producing potential 
The abuse liability and dependence producing potential of isotonitazene have not been studied. 
However, the abuse liability and dependence producing potential of etonitazene and metonitazene, 
both closely related homologues to isotonitazene, as well other members of this group, have been 
studied to varying degrees (Ujváry, 2020).  
Information on etonitazene 
In morphine-addicted rhesus monkeys which had received 3 mg/kg morphine for at least 3 months, 
subcutaneously injected etonitazene was 1500-fold while clonitazene was only two-fold more potent 
than morphine sulfate in suppressing abstinence signs; the onset was rapid but the duration of action 
of both of these benzimidazoles was less than that of morphine. At the highest dose (0.002 mg/kg), 
jaw and body sag, scratching and rubbing face were noted (Deneau et al., 1959; Aceto et al., 1992). 
The results of a single-dose substitution (SDS) test with morphine (3.0 mg/kg) and etonitazene 
(0.0005 mg/kg and 0.002 mg/kg) subcutaneous doses in rhesus monkeys are shown in Figure 4. 
FIGURE 4 
Single-dose substitution of morphine by two doses of etonitazene in rhesus monkeys showing 
withdrawal signs after abrupt cessation of chronic morphine treatment (Aceto et al., 1992). 
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The reinforcing properties of etonitazene have been demonstrated in several animal models. For 
example, in rhesus monkeys, orally administered etonitazene was established as a positive reinforcer 
(Carroll and Meisch, 1978). 
In self-administration experiments with rhesus monkeys (Achat-Mendes et al., 2009), etonitazene and 
heroin appeared to have different reinforcing properties: heroin was consistently self-injected (0.001–
0.01 mg/kg dose range) while etonitazene failed to maintain significant levels of self-administration 
(0.001–1.0 μg/kg dose range (17)). It was however noted that self-administration of an etonitazene + 
cocaine combination maintained a significantly greater number of injections than did cocaine alone. 
Furthermore, the MOP receptor antagonist naltrexone blocked self-administration of both 
etonitazene+cocaine and heroin+cocaine combinations, but not of cocaine self-administration 
suggesting that MOP receptor mechanisms are important in mediating the ‘speedball‘ effect. 
In a human pain-treatment clinical study with clonitazene administered either by injection (repeated 
15–30 mg subcutaneous or intramuscular doses) or orally (repeated 50 mg doses), tolerance did not 
appear to have developed after a 35-day continuous treatment and no craving was observed in the 
patients (Bromig, 1958). 
In stabilised morphine addicts, one mg etonitazene orally was equivalent to 59.3 mg morphine 
subcutaneously (about 60-fold difference) as suppressant of abstinence phenomena (Eddy, 1959). 
The addictive potential in man of orally administered clonitazene and etonitazene, as compared to 
morphine, was studied in non-tolerant former morphine addicts at the Addiction Research Center, US 
Public Health Service Hospital of the US National Institute of Health (Fraser et al., 1960; Wikler, 
1960). In ‘single dose’ oral administrations, clonitazene (NIH-7586; 100 mg) appeared to be about 
one-third to one-fifth as potent as morphine sulfate (20 and 30 mg) and roughly equivalent to codeine 
(60 or 90 mg), while etonitazene (NIH-7607; 0.25 mg) was more than 80 to 120 times as effective as 
morphine as a euphoriant. Both clonitazene and etonitazene caused miosis. Furthermore, both drugs 
suppressed abstinence symptoms: 2.62 mg of clonitazene orally was equivalent to 1 mg of morphine 
given subcutaneously while 1 mg of etonitazene orally, was equivalent to 59.3 mg morphine 
subcutaneously. In double-blind direct addiction tests involving 8 patients, orally administered 
etonitazene was not always classified as subcutaneously injected morphine- or heroin-like; in some 
cases effects resembling barbiturates were mentioned. Though patients reported preference to 
morphine or heroin over etonitazene, they were impressed by the hypnotic actions of etonitazene. 
Abrupt discontinuation following repeated administration of etonitazene, morphine or heroin, 
‘moderately severe abstinence syndrome ensued during the next ten days’. The study concluded that 
both clonitazene and etonitazene have addictive potential comparable to that of morphine. 
It is of note that that no euphoria was observed in patients receiving clonitazene 30 mg parenteral or 
50 mg oral doses during a pain treatment trial (Bromig, 1958).  
In 1960, in their assessment etonitazene and clonitazene the World Health Organization (WHO) 
Expert Committee on Addiction-Producing Drugs stated their ability to produce morphine-like effects, 
to suppress abstinence phenomena of a known morphine addiction, as well as to sustain morphine 
addiction, and recommended both drugs to be placed under international control (ECAPD, 1961). 
 
(17) Doses above 1.0 µg/kg cause significant respiratory depression in monkeys (Butelman et al., 1993). 
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Tolerance, or dose escalation in illicit opioid users in particular, apparently develops for all opioids and 
this observation extends to etonitazene (Walker and Young, 2001; Morgan and Christie, 2011). 
Information on metonitazene 
In morphine-addicted monkeys, subcutaneously injected metonitazene was a hundred-times more 
potent than morphine sulfate (0.03 mg/kg versus 3 mg/kg) in suppressing abstinence signs; the 
duration of action is about one-half that of morphine (Deneau et al., 1959; Ujvary, 2020). 
5. Extent and patterns of use, availability, and potential for diffusion 
5.1 Summary  
There is limited information on the extent and patterns of use, availability, and potential for diffusion of 
isotonitazene in Europe. 
Isotonitazene has been available on the drug market in Europe since at least April 2019, when it was 
seized for the first time by police in Estonia. The most recent identification of isotonitazene reported to 
the EMCDDA is a seizure made by police in Latvia in January 2020. As of 1 May 2020, it has been 
identified in six Member States: Belgium, Estonia, Germany, Latvia, Sweden, and the United 
Kingdom. These detections relate to police seizures reported by Estonia, Germany, and Latvia; a 
customs seizure reported by Sweden; a collected sample reported by Belgium; and biological 
samples from a death case reported by the United Kingdom. While the seized quantities are relatively 
small, they should be seen within the context of the possible high potency of isotonitazene (Section 
4.1).  
It appears that at least some of the isotonitazene on the market in Europe has been produced by 
chemical companies based in China, although the size and scale of this production is unknown. 
Isotonitazene is sold online as a powder in wholesale and small amounts; it is also sold as ready to-
use nasal sprays. Based on limited information from police seizures reported from two Member States 
(Estonia and Latvia) it is presumed, but not confirmed, that isotonitazene has been sold on the illicit 
opioid market at street-level and being injected intravenously by people who use opioids. 
Isotonitazene may be deliberately sought after by some users, such as those who self-experiment 
with a range of psychoactive substances (so-called ‘psychonauts’) (Section 2.6); others, such as 
those that purchase it at street-level, may be unaware that they are using the substance which 
presents an inherent risk to the individuals. Although the drug situation is different from Europe, 
information from a case series of 18 deaths with confirmed exposure to isotonitazene in the United 
States found that at least some of the individuals were high risk drug users and included people who 
had a history of injecting opioids such as heroin (Krotulski et al., 2020; Power, 2020). In addition, 
isotonitazene was identified along with one or more other psychoactive substances (controlled drugs 
and new psychoactive substances) in all the deaths, which suggests that polydrug use was common 
in these individuals (Krotulski et al., 2020). In particular, the use of other CNS depressants such as 
other opioids and benzodiazepine sedative/hypnotics was very common in these individuals (Section 
6.2.2). 
As isotonitazene has only been on the drug market for a short period of time, it may not be part of 
drug screening in many forensic and toxicology laboratories in Europe. Therefore, the presence of 
isotonitazene on the European drug market may be undetected in some areas, including in law 
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enforcement seizures as well as in biological samples related to serious adverse events. Furthermore, 
analytical sensitivity related to the analysis of biological samples from serious adverse events may 
also be a potential issue as the concentration of isotonitazene or its metabolites can be sub-
nanogram to picogram (similar to the highly potent opioid carfentanil) which highlights a need for 
increased analytical sensitivity when testing for the substance. In addition, due to differences in 
reporting practices across Europe, identifications of isotonitazene may be unreported to the Reitox 
national focal points, and, as a result, to the EMCDDA. It is also important to note that, in some 
settings, there may be delays in detecting and reporting detections of isotonitazene due to reduced 
capacity of early warning systems, including forensic science and toxicology laboratories, as a result 
of the impact of the ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) (ECDC, 2020; WHO, 2020). 
More generally, the impact of the ongoing COVID-19 pandemic (ECDD, 2020; WHO, 2020) on the 
manufacture, trafficking, distribution, and use of isotonitazene is currently unknown. Based on 
previous experiences with disruptions to the illicit opioid markets (Ciccarone, 2019; EMCDDA, 2011; 
EMCDDA, 2012; Mars et al., 2019), it is conceivable, that, should there be a reduced availability of 
established illicit opioids in Europe, such as heroin as well as fentanyl and its derivatives, then 
criminal groups, as well as people who use opioids, especially high risk opioid users, may substitute 
these substances for a range of other substances, including 2-benzylbenzimidazole opioids such as 
isotonitazene. These changes may be geographically localised or broader, they may also be single 
‘one off’ events, or short-lived, or longer lasting changes. Similar to the recent experience with highly 
potent fentanyl derivatives, such as acryloylfentanyl and carfentanil, such changes to the drug market 
may increase the risk of life-threatening poisoning, as, currently, there is little to no experience with 
the use of isotonitazene (such as how to dose the substance and the effects it can cause); in some 
cases such substitution could manifest as outbreaks of poisoning (EMCDDA, 2018; Evans-Brown and 
Sedefov, 2018; Ujváry et al., 2017). These risks will be especially high in the case of people who 
obtain isotonitazene from street-level illicit opioids markets who are unlikely to be aware that they are 
using the substance. 
5.2 Information from seizures 
Law enforcement seizures of isotonitazene have been reported to the EMCDDA by four Member 
States: Estonia, Latvia, Germany, and Sweden. In total, 24 seizures were reported (1 made by 
customs; 23 made by police). In 22 cases isotonitazene was seized in powder form (total of 109.6 g of 
powder) and in two cases in liquid form (4.5 g). Where known, the seizures took place between April 
2019 and January 2020. 
5.2.1 Customs seizures  
Sweden reported a seizure of isotonitazene that was made by customs. The seizure took place in 
September 2019. A total of 48.8 g of powder was seized; the colour was described as yellow. 
Information on the amount of isotonitazene present in the seized powder (chemical purity) was not 
reported. The seized package originated from China and the destination was Sweden. 
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5.2.2 Police seizures  
A total of 23 seizures of isotonitazene made by police were reported three Member States: Estonia 
(n=17), Latvia (n=4), and Germany (n=2) (18). Where known, the seizures took place between April 
2019 and January 2020.  
In 21 cases, isotonitazene was seized in powder form totalling 60.8 g (range 0.013 to 19.8 g); the 
colour of the powder was described as brown in some of the cases reported by Estonia. Information 
on the amount of isotonitazene present in the seized powders (chemical purity) was not reported. 
Estonia reported that the only other substances detected in the powders were ‘common sugars’ (not 
further specified); Latvia reported that one seizure also contained fentanyl. Estonia reported that 
some of the seizures related to small-scale distribution/supply. In one case reported by Latvia, 
powders of isotonitazene were found in 19 individual foil packages also suggesting small-scale 
distribution/supply.  
In two cases reported by Germany, the seized products were liquids (product name: ‘ISOTONITAZEN 
EXTRA STRONG‘) and also contained trace amounts of the synthetic cannabinoid 5F-MDMB-
P7AICA. Information on the amount of isotonitazene present in the seized liquids (strength) was not 
reported. 
5.3 Information from collected samples  
Belgium reported a collected sample of isotonitazene to the EMCDDA. It was a test purchase made 
by the national focal point via a private Telegram-group linked to a private website. The sample was 
incorrectly advertised as ‘etonitazene’. The cost was $400 per 1 g. It was received as a white powder 
in a plastic zip-lock bag which was then packaged inside a foil bag, with the label ‘iso’. Based on the 
analyses conducted it was reported that the sample was of ‘high purity’ (Blanckaert et al., 2020). 
5.4 Information from biological samples 
The United Kingdom reported post-mortem biological samples (blood and urine) to the EMCDDA from 
a death in which isotonitazene was identified. Butyrylfentanyl, despropionyl fentanyl (4-ANPP), and 
despropionyl fluorofentanyl were also identified in the biological samples. All the substances were 
estimated to be at sub ng/ml) levels. The death occurred in 2019; no further details are currently 
available (Section 6.2.2).  
6. Health risks 
6.1 Summary 
Based on the available information for isotonitazene the most serious acute health risk from 
isotonitazene is likely to be respiratory depression, which in overdose could lead to apnoea, 
respiratory arrest, and death (Pattinson, 2008; Romberg et al., 2003; White and Irvine, 1999). 
Although there is no reported clinical experience with poisonings cases by jsotonitazene, based on 
 
(18) Seizures of isotonitazene made by police have also been reported in Canada. Physical forms seized include powders and 
falsified (fake) opioid analgesic medicines (Section 2.6). 
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the pharmacological properties of the substance, naloxone is expected to work as an antidote (Boyer, 
2012; Kim and Nelson, 2015). Similarly to other opioids analgesics, the use of isotonitazene with 
other central nervous system (CNS) depressants, is likely to produce additive depressant effects 
which can increase the risk of life-threatening respiratory depression and arrest (US FDA, 2016). 
A total of 2 deaths involving isotonitazene have been reported to the EMCDDA. The role of 
isotonitazene in these deaths is unknown. 
There is no information on the chronic health effects of isotonitazene, including abuse liability and 
dependence production potential. Similar to established opioids, the chronic health risks might share 
some similarities to those seen with established illicit opioids, such as heroin and fentanyl. This may 
include dependence. 
6.2 Acute health effects 
Based on the available information for isotonitazene, as well as for etonitazene and metonitazene, 
both closely related homologues to isotonitazene, as well other members of this group, and, similar to 
other MOP receptor agonists, the most serious acute health risk from isotonitazene is likely to be 
respiratory depression, which in overdose could lead to apnoea, respiratory arrest, and death 
(Pattinson, 2008; White and Irvine, 1999). This risk may be greater due to the fact that isotonitazene 
is the first of the 2-benzylbenzimidazole opioids to be identified on the drug market in recent years, 
and users have no experience with this family of opioids, including a lack of information on what 
doses to use and what effects the substance can have.  
Although there is no information on the clinical features of poisoning caused by isotonitazene, they 
are likely to include the opioid overdose triad of miosis, reduced level of consciousness or 
unconsciousness, and respiratory depression. 
Although there is no reported clinical experience with poisonings caused by isotonitazene, based on 
the pharmacological properties of the substance, naloxone is expected to work as an antidote in 
reversing respiratory depression (Boyer, 2012; Kim and Nelson, 2015). 
Similarly to other opioids analgesics, the use of isotonitazene with other central nervous system 
(CNS) depressants, including other opioids, sedatives/hypnotics, alcohol, pregabalin, gabapentin, 
tranquillisers, and sedating anti-histamines, is likely to produce additive depressant effects which can 
increase the risk of life-threatening respiratory depression and arrest (US FDA, 2016). Information 
from Europe on polydrug use with isotonitazene is limited to a single death case reported by the 
United Kingdom where other opioids, specifically fentanyl derivatives, were identified. Although the 
drug situation is different from Europe, information from a case series of 18 deaths in the United 
States found that polydrug use among these individuals was common, including a majority who used 
one or more CNS depressant, especially other opioids and benzodiazepine sedative/hypnotics.  
6.2.1 Acute poisonings 
No cases of acute poisoning involving isotonitazene have been reported to the EMCDDA or published 
in the scientific literature. 
RISK ASSESSMENT REPORT I Isotonitazene 
43 
6.2.2 Deaths 
Deaths reported in Europe 
A total of two deaths involving isotonitazene have been reported to the EMCDDA by Germany and the 
United Kingdom. No further information is currently available for the death reported by Germany. The 
United Kingdom reported a death with confirmed exposure to isotonitazene that occurred in 2019. 
Alongside isotonitazene, butyrylfentanyl, despropionyl fentanyl (4-ANPP), and despropionyl 
fluorofentanyl were also identified in postmortem biological samples; all the substances were 
estimated to be below ng/ml concentrations. No further details on the case are currently available. 
The role of isotonitazene in these deaths is unknown. 
Deaths reported elsewhere 
Canada 
Isotonitazene has been identified in 3 deaths in Canada during 2019. The deaths occurred in Alberta 
in March, September, and October 2019. No further details are available (Toxicovigilance Canada, 
2019). The role of isotonitazene in these deaths is unknown. 
United States  
Krotulski et al. (2020) have recently published a report of 18 deaths with confirmed exposure to 
isotonitazene in the United States; all cases were medico-legal death investigations. The role of 
isotonitazene in these deaths is unknown. 
The deaths occurred between August 2019 and January 2020 and were from the Midwestern United 
States: Illinois (n=9), Indiana (7), Minnesota (1), and Wisconsin (1). The majority of individuals were 
male (n=12; 67%). The mean age was 41±12 years (median 41 years) and ranged from 24 to 66 
years. 
The mean concentration of isotonitazene in blood samples (N=18) was 2.2±2.1 ng/mL (median 1.75 
ng/mL, range 0.4-9.5 ng/mL) (central or peripheral blood). The lowest concentration of isotonitazene 
in blood was 0.4 ng/mL and was encountered in two cases in which no other opioids were present 
(case 8 and case 10). The mean concentration of isotonitazene in urine samples (N=6) was 2.4±1.4 
ng/mL (median 2.7 ng/mL, range 0.6-4.0 ng/mL). The concentration of isotonitazene in a single 
sample of vitreous fluid was 0.1 ng/mL. 
Isotonitazene was identified in all the biological samples that were analysed in this study (blood, urine, 
vitreous fluid), which may suggest the usefulness of this analyte for drug testing purposes. It is 
important to note that, similar to the highly potent opioid carfentanil, quantitative results for 
isotonitazene were low to sub-nanogram per millilitre concentrations, highlighting the need for 
increased analytical sensitivity when testing for the substance. Details on the identification and 
characterisation of metabolites in blood and urine are also provided in the report (Krotulski et al., 
2020) (Section 5.4). 
Based on information from the death investigations (n=8) and forensic toxicology results (n=18), at 
least some of the individuals were high risk drug users and included people who had a history of 
injecting  established illicit opioids, such as heroin and fentanyl. Isotonitazene was identified along 
with one or more other psychoactive substances (controlled drugs and new psychoactive substances) 
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in all the deaths, which suggests that polydrug use was common in these individuals. Briefly, among 
other findings in blood: 
§ In addition to isotonitazene, one or more other types of opioids were identified in 10 (56%) of 
the cases; these included fentanyl (n=6), morphine (n=3) (including 6-monoacetylmorphine in 
one case), tramadol (n=4), piperidylthiambutene (n=2), and U-47,700 (n=1). Isotonitazene 
was the only opioid identified in the remaining 8 cases. 
§ Benzodiazepines were identified in 16 (89%) of the cases; most of the identifications related 
to flualprazolam (n=11) or etizolam (n=8) (19). 
§ Stimulants were identified in 6 (33%) of the cases: cocaine was identified in 4 (22%) cases; 
amphetamine and methamphetamine were identified in 2 (11%) cases (in one of these cases 
MDMA and MDA were also identified). 
§ Naloxone (an antidote used in opioid overdose) was identified in 6 (33%) of the cases. This 
includes 2 cases where isotonitazene was the only opioid identified. 
6.2.3 Driving and operating machinery under influence 
The effect of isotonitazene on the ability to drive and operate machinery has not been studied. 
However, it is well established that opioid analgesics impair the mental and physical ability to drive 
and operate machinery. This effect is likely to extend to isotonitazene. 
6.3 Chronic health effects 
There is no information on the chronic health effects of isotonitazene. Similar to established opioids, 
the chronic health risks might share some similarities to those seen with  established illicit opioids, 
such as heroin and fentanyl. This may include dependence (Section 4.6). 
Based on the limited information reported to the EMCDDA from police seizures, it is presumed, but 
not confirmed, that isotonitazene is being injected intravenously by high risk opioid users in some 
parts of Europe. Although the drug situation is different from Europe, information from a case series of 
18 deaths with confirmed exposure to isotonitazene in the United States noted that at least some of 
the individuals were high risk drug users and included people who had a history of injecting opioids 
such as heroin (Krotulski et al., 2020). As such, and similar to the use of established illicit opioids, 
there is a risk of transmission of blood-borne infections, such as HIV, hepatitis B, and hepatitis C, if 
injecting equipment is shared (Degenhardt et al., 2016; EMCDDA, 2020b). 
7. Social risks 
There have been no studies on the social risks of isotonitazene. Given that isotonitazene acts as an 
opioid analgesic, any such risks may have some similarities with those associated with established 
illicit opioids such as heroin as well as fentanyl and its derivatives. 
 
(19) Flualprazolam and etizolam are monitored by the EMCDDA as new psychoactive substances. The substances were 
recently controlled under the United Nations Convention on Psychotropic Substances, 1971, over concerns of the public health 
threats that they pose (UNODC, 2020). 
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7.1 Individual social risks 
There is no information on the individual social risks that may be associated with the use of 
isotonitazene. Given that isotonitazene acts as an opioid analgesic, any such risks may have some 
similarities with those associated with established illicit opioids. These risks may negatively impact on 
education or career, family or other personal and social relationships and may result in 
marginalisation. 
7.2 Possible effects on direct social environment 
There is no information on the possible effects of isotonitazene on the direct social environment. 
Given that isotonitazene acts as an opioid analgesic, any such effects may have some similarities 
with those associated with the use of established illicit opioids. 
7.3 Possible effects on society as a whole 
There is no information on the possible effects of isotonitazene on society as a whole. Given that 
isotonitazene acts as an opioid analgesic, any such effects may have some similarities with those 
associated with the use of established illicit opioids. 
7.4 Economic costs 
There are no information on the health and social costs related to isotonitazene. Given that 
isotonitazene acts as an opioid analgesic, any such costs may have some similarities with those 
associated with the use of established illicit opioids. 
7.5 Possible effects related to the cultural context, for example marginalisation 
There is no information on the possible effects of isotonitazene related to the cultural context. Given 
that isotonitazene acts as an opioid analgesic, any such effects may have some similarities with those 
associated with the use of established illicit opioids. 
7.6 Possible appeal to specific population groups within the general population 
Based on limited information, alongside what appears to be small-scale interest in isotonitazene by 
people who self-experiment with psychoactive substances (so-called ‘psychonauts’), it is presumed, 
but not confirmed, that isotonitazene is being injected intravenously by high risk opioid users in some 
parts of Europe. Although the drug situation is different from Europe, information from a case series of 
18 deaths with confirmed exposure to isotonitazene in the United States noted that at least some of 
the individuals were high risk drug users and included people who had a history of injecting opioids 
such as heroin (Krotulski et al., 2020). Based on this information and that isotonitazene acts as an 
opioid analgesic, it is reasonable to assume that isotonitazene may be sought by those looking for 
‘legal’ substitutes for established illicit opioids, such as heroin, as well as fentanyl and its derivatives, 
and/or prescription opioids. 
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7.7 Involvement of criminal groups in the manufacture, distribution and distribution 
methods, and trafficking 
There is no information on whether or not criminal groups are involved in the manufacture, trafficking, 
and distribution of isotonitazene within Europe (EMCDDA, 2020a). The impact of the ongoing COVID-
19 pandemic (ECDD, 2020; EMCDDA, 2020b; WHO, 2020) on the manufacture, trafficking, 
distribution, and use of isotonitazene is also currently unknown. Based on previous experiences with 
disruptions to the illicit opioid markets (Ciccarone, 2019; EMCDDA, 2011; EMCDDA, 2012; Mars et 
al., 2019), it is conceivable, that, should the availability of established illicit opioids, such as heroin 
and/or fentanyl and its derivatives, be reduced in Europe, then criminal groups, as well as people who 
use opioids, especially high risk opioid users, may substitute these substances for a range of other 
substances, including 2-benzylbenzimidazole opioids such as isotonitazene.   
8. Other relevant information  
8.1 Information on restrictive measures 
8.1.1 International restrictive measures 
At international level, Isotonitazene is not controlled under the United Nations Single Convention on 
Narcotic Drugs, 1961, as amended by the 1972 Protocol, or the Convention on Psychotropic 
Substances of 1971 (‘United Nations system’) (UNODC, 2019a; UNODC, 2019b). Isotonitazene has 
not been subject to assessment nor is it currently under assessment by the United Nations system 
(EMCDDA, 2020a). 
 8.1.2 National restrictive measures 
Twenty two Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, 
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, the Netherlands, 
Portugal, Romania, Slovakia, Slovenia, and Spain) reported that isotonitazene is not subject to 
restrictive measures at national level. Turkey also reported that isotonitazene is not subject to 
restrictive measures at national level (EMCDDA, 2020a). 
Isotonitazene is subject to restrictive measures in six Member States: in Estonia, Latvia, Poland, and 
Sweden the substance is controlled under drug control legislation; in Lithuania it is controlled under 
medicines legislation; while in the United Kingdom it is controlled by new psychoactive substance 
legislation. In addition, isotonitazene is controlled under medicines legislation in Norway (EMCDDA, 
2020a).  
It is unknown if isotonitazene is controlled in China, where at least some of the substance on the 
European market has been sourced from. 
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